UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 10-Q



Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended December 31, 20172021

Transitionreport underpursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission file number 1-32830number: 001-32830

indiaglob20211231_10qimg001.jpg

INDIA GLOBALIZATION CAPITAL, INC.

(Exact name of registrant as specified in its charter)

Maryland

(State or other jurisdiction of incorporation or organization)

20-2760393

(I.R.S. Employer Identification No.)

4336 Montgomery Ave. Bethesda,

10224 Falls Road, Potomac, Maryland

(Address of principal executive offices)

20814 

20854

(Zip Code)

(301) 983-0998

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Tradingsymbol(s)

Name of each exchange on whichregistered

Common Stock, par value $0.0001 per share

IGC

NYSE American LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer

Accelerated filer

Non-accelerated filer

(Do not check if a smaller reporting company) 

Smaller reporting company

Emerging growth company

company☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No


There were approximately 30,282,053

51,054,017 shares of our common stock par value $0.0001, issued andwere outstanding as of January 31, 2018.2022.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

 




INDIA GLOBALIZATION CAPITAL, INC.

QUARTERLY REPORT ON

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 20172021


Table of Contents


Page

PART I –I. FINANCIAL INFORMATION

Item 1.

3

4

3

4

4

5

5

6

6

7

  7

8

Item 2.

14

26

Item 3.

17

33

Item 4.

17

33

PART II –II. OTHER INFORMATION

Item 1.

18

34

Item 1A.

18

35

Item 2.

18

35

Item 3.

18

35

Item 4.

18

35

Item 5.

18

35

Item 6.

18

35

SIGNATURES

19

36



indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q


FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and the documents incorporated herein by reference contain forward-looking statements. Additionally, we, or our representatives, may, from time to time, make other written or verbal forward-looking statements and discuss plans, expectations, and objectives regarding our business, financial condition, and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as believe,project,expect,trend,estimate,forecast,assume,intend,plan,target,anticipate,outlook,preliminary,will likely result,will continue and variations of them and similar terms are intended to be forward-looking statements as defined by federal securities laws. Such statements are based on currently available information, which management has assessed but which is dynamic and subject to rapid change due to risks and uncertainties that affect our business.

For the next several years, we believe our success is highly correlated with improvement in the Hong Kong and Indian economies, particularly their recovery from the ongoing SARS-CoV-2 (COVID-19) pandemic and with the outcome of our clinical trials and secondarily on the sale of our products and services. The Company may not be able to complete human trials on our investigational drug candidates, or, once conducted, the results of human trials may not be favorable or as anticipated or may reflect lack of efficacy in humans or animals. Precautions including social distancing and travel restrictions, among others, surrounding the COVID-19 pandemic could lead to delays or expenses greater than anticipated or projected. Failure or delay with respect to any of the above factors could have a material adverse effect on our business, future results of operations, stock price, and financial condition.

Our projections and investments anticipate certain regulatory changes and stable pricing, which may not hold out over the next several years. We may not be able to protect our intellectual property adequately or receive patents. We may not receive regulatory approval for our products, or trials. The patent applications we have licensed may not be granted by the United States Patent and Trademark Office (USPTO), even if the Company is in full compliance with USPTO requirements. We may not have adequate resources including financial resources, to successfully conduct all requisite clinical trials, to bring a product based on the above-referenced patented formulations to market, or to pay applicable maintenance fees over time. We may not be able to successfully commercialize our products even if they are successful and receive regulatory approval, including, but not limited to, based on the Food & Drug Administrations (FDA) current position on hemp and hemp-based products. Failure or delay with respect to any of the factors above could have a material adverse effect on our business, future results of operations, stock price, and financial condition.

This document also contains statements that are not approved by the FDA, including statements on hemp and hemp extracts and their potential efficacy on humans and animals. While these statements and claims are intended to be in compliance with federal and state laws, we cannot guarantee such compliance.

We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans, and projections subject to risks and uncertainties, including those, if any, identified in the Risk Factors set forth in this report or in our annual report on Form 10-K for the fiscal year ended March 31, 2021, filed with the Securities and Exchange Commission (SEC) on June 14, 2021, or in our quarterly reports on Form 10-Q for the three months ended June 30, 2021, and September 30, 2021, respectively, and in the documents incorporated by reference that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q



PART I FINANCIAL INFORMATION


Item 1. Financial Statements

INDIA GLOBALIZATION CAPITAL, INC.

India Globalization Capital, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS


(All amounts in USD,thousands, except number of shares)share data)

(Unaudited)

  As of 
  31-December- 17  31-March - 17 
  (unaudited)  (audited) 
ASSETS      
Current assets:      
Cash and cash equivalents $1,690,792  $538,029 
Accounts receivable, net of allowances  1,155,229   752,926 
Prepaid expenses and other current assets  379,785   410,408 
Short-term investments  -   1,880,000 
Total current assets $3,225,806  $3,581,363 
Goodwill  198,169   198,169 
Intangible assets  124,272   - 
Property, plant and equipment, net  951,351   953,936 
Investment  6,015,634   6,011,114 
Other non-current assets  820,913   539,720 
Total long-term assets $8,110,339  $7,702,939 
Total assets $11,336,145  $11,284,302 
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current liabilities:        
Trade payables  674,882   416,532 
Accrued expenses  175,200   181,465 
Other current liabilities  474,101   691,714 
Total current liabilities $1,324,183  $1,289,711 
Long-term borrowings  -   452,080 
Loans- others  737,097   392,226 
Notes payable  1,800,000   1,800,000 
Total non-current liabilities $2,537,097  $2,644,306 
Total liabilities $3,861,280  $3,934,017 
Stockholders’ equity:        
Common stock — $.0001 par value; 150,000,000 shares authorized; 28,272,667 issued and outstanding as of March 31, 2017 and 29,499,790 issued and outstanding as of December 31, 2017. $2,950  $2,827 
Additional paid-in capital  62,737,631   61,413,533 
Accumulated other comprehensive income  (2,037,529)  (2,047,780)
Retained earnings/(deficit)  (53,219,180)  (52,009,459)
Total equity attributable to Parent $7,483,872  $7,359,121 
Non-controlling interest $(9,007) $(8,836)
Total stockholders’ equity $7,474,865  $7,350,285 
Total liabilities and stockholders’ equity $11,336,145  $11,284,302 

  

December 31,

2021

($)

  

March 31,

2021

($)

 

ASSETS

        

Current assets:

        

Cash and cash equivalents

  11,941   14,548 

Accounts receivable, net

  164   175 

Inventory

  5,428   5,478 

Investment in Non-marketable securities

  -   80 

Deposits and advances

  1,704   3,236 

Total current assets

  19,237   23,517 

Non-current assets:

        

Intangible assets, net

  426   407 

Property, plant and equipment, net

  10,520   10,840 

Non-marketable securities

  11   12 

Claims and advances

  612   603 

Operating lease asset

  482   488 

Total non-current assets

  12,051   12,350 

Total assets

  31,288   35,867 

LIABILITIES AND STOCKHOLDERS EQUITY

        

Current liabilities:

        

Accounts payable

  357   476 

Accrued and other liabilities

  919   1,588 

Short-term loans

  3   304 

Total current liabilities

  1,279   2,368 

Non-current liabilities:

        

Long-term loans

  145   276 

Other liabilities

  15   15 

Operating lease liability

  374   405 

Total non-current liabilities

  534   696 

Total liabilities

  1,813   3,064 
         

Commitments and Contingencies See Note 12

        
         

Stockholders equity:

        

Preferred stock, $0.0001 par value: authorized 1,000,000 shares, 0 shares issued or outstanding as of December 31, 2021, and March 31, 2021.

  -   - 

Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 51,054,017 and 47,827,273 shares issued and outstanding as of December 31, 2021, and March 31, 2021, respectively.

  114,894   109,720 

Accumulated other comprehensive loss

  (2,763)  (2,774

)

Accumulated deficit

  (82,656)  (74,143

)

Total stockholders equity

  29,475   32,803 

Total liabilities and stockholders equity

  31,288   35,867 
See

The accompanying Notes tonotes should be read in connection with these Condensed Consolidated Financial Statements belowStatements.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

India Globalization Capital, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except loss per share and share data)

(Unaudited)

  

Three months ended

December 31,

  

Nine months ended

December 31,

 
  

2021

  

2020

  

2021

  

2020

 
  ($)  ($)  ($)  ($) 
                 

Revenue

  142   108   275   817 

Cost of revenue

  (80)  (94)  (149)  (731)

Gross Profit

  62   14   126   86 

Selling, General and administrative expenses

  (2,070)  (2,186)  (7,956)  (5,424)

Research and development expenses

  (377)  (154)  (1,097)  (595)

Operating loss

  (2,385)  (2,326)  (8,927)  (5,933)

Impairment of investment

  -   -   (37)  - 

Other income, net

  4   3   451   71 

Loss before income taxes

  (2,381)  (2,323)  (8,513)  (5,862)

Income tax expense/benefit

  -   -   -   - 

Net loss attributable to common stockholders

  (2,381)  (2,323)  (8,513)  (5,862)

Foreign currency translation adjustments

  77   40   11   124 

Comprehensive loss

  (2,304)  (2,283)  (8,502)  (5,738)
                 

Net Loss per share attributable to common stockholders:

                

Basic and Diluted

 $(0.05)  (0.06

)

  (0.18)  (0.14)

Weighted-average number of shares used in computing net loss per share amounts:

  51,053,191   41,304,365   49,643,942   40,915,196 

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q5

India Globalization Capital, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

(in thousands)

(Unaudited)

Three months ended December 31, 2020

 

Number of

Common Shares

  

Common Stock and

Additional Paid in

Capital

($)

  

Accumulated

Deficit

($)

  

Accumulated Other

Comprehensive Loss

($)

  

Total Stockholders’

Equity

($)

 

Balances as of September 30, 2020

  41,304   95,270   (68,906)  (2,766)  23,598 

Common stock-based compensation & expenses, net

  -   157   -   -   157 

Net loss

  -   -   (2,323)  -   (2,323)

Loss on foreign currency translation

  -   -   -   40   40 

Balances as of December 31, 2020

  41,304   95,427   (71,229)  (2,726)  21,472 
                     

Three months ended December 31, 2021

                    

Balances as of September 30, 2021

  51,041   114,371   (80,275)  (2,840

)

  31,256 

Common stock-based compensation & expenses, net

  13   523   -   -   523 

Issuance of common stock through offering (net of expenses)

  -   -   -   -   - 

Net loss

  -   -   (2,381)  -   (2,381)

Loss on foreign currency translation

  -   -   -   77   77 

Balances as of December 31, 2021

  51,054   114,894   (82,656)  (2,763)  29,475 

Nine months ended December 31, 2020

 

Number of

Common Shares

  

Common Stock and

Additional Paid in

Capital

($)

  

Accumulated

Deficit

($)

  

Accumulated Other

Comprehensive Loss

($)

  

Total Stockholders’

Equity

($)

 

Balances as of March 31, 2020

  39,320   94,754   (65,367

)

  (2,850

)

  26,537 

Common stock-based compensation & expenses, net

  1884   573   -   -   573 

Common stock issued for investment

  100   100   -   -   100 

Net loss

  -   -   (5,862

)

  -   (5,862

)

Loss on foreign currency translation

  -   -   -   124   124 

Balances as of December 31, 2020

  41,304   95,427   (71,229

)

  (2,726

)

  21,472 
                     

Nine months ended December 31, 2021

                    

Balances as of March 31, 2021

  47,827   109,720   (74,143

)

  (2,774

)

  32,803 

Common stock-based compensation & expenses, net

  1,520   1,072   -   -   1,072 

Issuance of common stock through offering (net of expenses)

  1,750   4,145   -   -   4,145 

Other adjustments

  (43)  (43)  -   -   (43)

Net loss

  -   -   (8,513)  -   (8,513)

Gain on foreign currency translation

  -   -   -   11   11 

Balances as of December 31, 2021

  51,054   114,894   (82,656)  (2,763)  29,475 

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

India Globalization Capital, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

  

Nine months ended

December 31,

 
  

2021

($)

  

2020

($)
 

Operating activities:

        

Net loss

  (8,513)  (5,862)

Adjustment to reconcile net loss to net cash:

        

Depreciation and amortization

  486   312 

Provision for bad debt

  1,718   - 

Impairment of non-marketable securities

  37   - 

Common stock-based compensation and expenses

  1,072   523 

Forgiveness of PPP Loan

  (430)  - 
         

Changes in:

        

Accounts receivables

  11   (93)

Inventory

  51   (911)

Deposits and advances

  (186)  (2,031)

Claims and advances

  (10)  55 

Accounts payable

  (117)  112 

Accrued and other liabilities

  (669)  (400)

Operating lease asset

  6   - 

Operating lease liability

  (31)  - 

Net cash used in operating activities

  (6,575)  (8,295)
         

Investing activities:

        

Purchase of property, plant, and equipment

  (152)  (1,381)

Proceed from marketable securities

  -   3,081 

Investment in non-marketable securities

  -   (149)

Acquisition and filing cost of patents and rights

  (37)  (92)

Net cash (used in)/provided by investing activities

  (189)  1,459 
         

Financing activities:

        

Issuance of equity stock through offering (net of expenses)

  4,145   - 

Proceeds from/Repayment of long- term loan

  (2)  530 

Net cash provided by financing activities

  4,143   530 
         

Effects of exchange rate changes on cash and cash equivalents

  14   16 

Net decrease in cash and cash equivalents

  (2,607)  (6,290)

Cash and cash equivalents at the beginning of the period

  14,548   7,258 

Cash and cash equivalents at the end of the period

  11,941   968 
         

Supplementary information:

        

Non-cash items:

        

Common stock issued/granted for stock-based compensation, including patent acquisition

  1,072   573 

Amortization of operating lease

  80   20 

Forgiveness of PPP Loan

  (430)  - 

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

India Globalization Capital, Inc.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED DECEMBER 31, 2021

(in thousands, except for share data and loss per share, unaudited)

Unless the context requires otherwise, all references in this report to IGC,the Company,we,our and/or us refer to India Globalization Capital, Inc., together with our subsidiaries and beneficially owned subsidiary. Our filings are available on www.sec.gov. The information contained on our various websites, including www.igcinc.us, is not incorporated by reference in this report, and you should not consider such information to be a part of this report. We exclude our investments and minority non-controlling interests, and any information provided by them is not incorporated by reference in this report, and you should not consider such information to be a part of this report.

NOTE 1 BUSINESS DESCRIPTION

Business

Since 2014, we have focused a portion of our business on the Notesapplication of phytocannabinoids such as Tetrahydrocannabinol (“THC”) and Cannabidiol (“CBD”), among others, in combination with other compounds, to address efficacy for various ailments and diseases such as Alzheimer’s disease. As previously disclosed, IGC submitted IGC-AD1, our investigational drug candidate for Alzheimer’s, to the Audited Consolidated Financial Statements containedU.S. Food and Drug Administration (“FDA”) under Section 505(i) of the Federal Food, Drug, and Cosmetic Act and received approval on July 30, 2020, to proceed with the Phase 1 trial on Alzheimer’s patients.

The Company completed all dose escalation studies, and, as announced by the Company on December 2, 2021, the results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA. The Company is motivated by the potential that, with future successful results from appropriate further trials, IGC-AD1 could contribute to relief for some of the 50 million people around the world expected to be impacted by Alzheimer’s disease by 2030 (WHO, 2020).

At the start of the trial, the participants receiving the active drug (N=11) had an average age and weight of 81.5 years (SD 5.5) and 138.8 lb (SD 24.7) respectively. The placebo participants (N=2) had an average age and weight of 75 years (SD 4.2) and 196.4 lb (SD 17.0) respectively.

Primary Endpoint: Safety & Tolerability (S&T):

S&T was assessed by recording both solicited and non-solicited Adverse Events (AEs). The solicited AEs, assessed daily, were somnolence, falls, dizziness, asthenia, suicidal ideation, hypertension, psychiatric symptoms, and paradoxical nausea. All AEs were graded as mild, moderate, severe, life threatening, and serious (SAE).

In all three Cohorts, a) there were no SAEs, b) no life-threatening AEs, and c) no deaths.

One AE, mild dizziness, reported in Cohort 1, was deemed to be related to IGC-AD1. All other AEs across all cohorts were deemed to be not related to IGC-AD1 or to the placebo.

In Cohort 1, in the group that received IGC-AD1 (N=10), 50% reported hypertension, 40% reported asthenia, 30% reported somnolence and dizziness, 20% reported psychiatric symptoms and 10% reported falls. One case of dizziness was deemed by the principal investigator (PI) to be related to IGC-AD1. In the placebo group (N=2) 100% reported hypertension, and 50% reported somnolence and falls.

In Cohort 2 for the IGC-AD1 group, 60% reported psychiatric symptoms, 50% reported somnolence and asthenia, 30% reported hypertension, 20% reported nausea and dizziness, and 10% reported falls and suicidal ideation. In the placebo group 100% reported somnolence, 50% reported dizziness and hypertension.

In Cohort 3 for the IGC-AD1 group, 70% reported somnolence, 60% reported psychiatric symptoms, 50% reported dizziness and asthenia, and 30% reported hypertension. In the placebo group 100% reported somnolence, and 50% reported hypertension and psychiatric symptoms.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Secondary Endpoints: Neuropsychiatric Inventory (NPI):

Neuropsychiatric Symptoms (NPS) such as delusions, hallucinations, agitation/aggression, depression, anxiety, elation/euphoria, apathy, disinhibition, irritability, aberrant motor behavior, sleep disorders, and appetite/eating disorders are prevalent in patients who have Alzheimer’s disease (Phan et al., 2019). NPS in Alzheimer’s is a significant burden on patients and caregivers, and at some point, in the progression of Alzheimer’s disease, more than 97% of patients suffer from at least one symptom. The Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) measures the severity of each symptom and establishes both individual symptom scores as well as an overall NPI score. Separately, the NPI also scores caregiver distress (NPI-D). The NPI is used by about 50% of neurologists to assess and treat Alzheimer’s patients (Fernandez et al., 2010).

According to the NPI Test, a reduction of 4 points or 30% in the score is considered clinically meaningful. In addition, we also used a paired 2-tailed t-test with 9 degrees of freedom to assess the statistical significance of the decrease both in the overall NPI and individual NPI domains.

In Cohort 1 for those on IGC-AD1, the mean NPI decreased from a baseline 31.5 (SD 27.2) to 16.7 (SD 16.2) on day 10 (p = 0.0044) and 14.8 (SD 16.0) on day 15 (p = 0.0095).

o

Individual domains that showed improvement were Agitation (p = .05), Dilutions (p = .05), Anxiety (p = .09), and Appetite and Eating Disorders (p = .01).

In Cohort 2 for those on IGC-AD1, the mean NPI decreased from a baseline of 22.2 (SD 14.8) to 10.4 (SD 11.5) on day 10 (p = 0.0026) and 12.4 (SD14.7) on day 15 (p = 0.0127).

o

Individual domains that showed improvement were Agitation (p = .06), Irritability (p = .04), and Depression (p = .01).

In Cohort 3 for those on IGC-AD1 the mean NPI decreased from a baseline of 16.0 (SD14.7) to 14.6 (SD10.9) on day 10 (p = 0.6751) and 7.9 (SD 9.0) on day 15 (p = 0.0113).

o

Individual domains that showed improvement was Agitation (p = .06).

There was a non-clinically significant improvement between baseline and day 10 in Cohort 3 (NPI dropped less than 4 points and (p >> .05).

o

This may be related to the overall decrease of mean NPI between cohort baselines, Cohort 1 = 31.5, Cohort 2 = 22.2, Cohort 3 = 16.0 and that further improvement from a mean NPI = 16.0 takes longer, as measured on day 15 (mean NPI = 7.9).

To the best of our knowledge, this is the first human clinical trial using ultra low doses of THC, in combination with another molecule, to treat symptoms of dementia in Alzheimer’s patients. THC is a naturally occurring cannabinoid produced by the cannabis plant. It is known for being a psychoactive substance that can impact mental processes in a positive or negative way depending on the dosage. THC is biphasic, meaning that low and high doses of the substance may affect mental and physiological processes in substantially different ways. For example, in some patients, low doses may relieve a symptom, whereas high doses may amplify a symptom. Ultimately, the goal of IGC’s research is to discover and analyze whether, and at what level of dosing, IGC-AD1 provides relief of a given symptom. IGC’s trial is based on micro dosing on patients suffering from Alzheimer’s disease. With further trials, subject to FDA approvals, the Company intends to pursue the efficacy of IGC-AD1 for indications of Agitation in patients with dementia from Alzheimer’s.

The Company has filed thirteen (13) patent applications to address various diseases such as Alzheimer’s, Central Nervous System (“CNS”) disorders, pain, stammering, seizures in cats and dogs, eating disorders, stress-relief, and calm-restoring beverage, and fatigue. As of December 31, 2021, we have three patents.

In addition, we license a patent filing from the University of South Florida titled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease.” The U.S. Patent and Trademark Office (“USPTO”) issued a patent (#11,065,225) for this filing on July 20, 2021. The granted patent relates to IGC’s proprietary formulation, IGC-AD1, intended to assist in the treatment of individuals living with Alzheimer’s disease.

The Company is developing three brands, including Holief™, among others. Holief™ is a non-GMO, vegan, natural, women’s line of over-the-counter (“OTC”) products aimed at addressing dysmenorrhea and premenstrual symptoms (“PMS”) in women. Holief™, in development, seeks to connect, via a cloud-based platform, women with health care professionals who can help address dysmenorrhea, or period cramps, and PMS. Approximately 31.3 million (Statista, 2021) women in America suffer from dysmenorrhea and PMS.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Since our inception, the Company has operated its Infrastructure business segment from India. The infrastructure business segment involves: (a) the execution of construction contracts, (b) the rental of heavy construction equipment, and (c) the purchase and resale of physical commodities used in infrastructure. Information about our infrastructure products and service offerings is available at www.igcinc.us. Unfortunately, the infrastructure sector has been severely hampered by the COVID-19 pandemic, especially in India and Hong Kong where the business is based.

COVID-19 update

Our infrastructure business is based in the state of Kerala, India, which is among the Indian states most affected by COVID-19, and Hong Kong with strict quarantine and travel restrictions. The restrictions continue to adversely impact our infrastructure business, financial condition, liquidity, and operations. While IGC remains committed to its Infrastructure business line and intends to continue pursuing the execution of construction contracts, the purchase and resale of physical commodities used in infrastructure, and the rental of heavy construction equipment as the pandemic allows, we have limited visibility into when economic conditions will recover in India and Hong Kong.

In response, we have oriented our current focus on a) the human trials on IGC-AD1 and getting an Alzheimer’s drug through trials and eventually to market, subject to FDA approval, and b) launching a cannabinoid-based women’s wellness line of products designed to assist in managing PMS and Dysmenorrhea.

Business Organization

As of December 31, 2021, the Company had the following direct operating subsidiaries: Techni Bharathi Private Limited (“TBL”), IGCare, LLC (“IGCare”), Holi Hemp, LLC (“Holi Hemp”), IGC Pharma, LLC (“IGC Pharma”), SAN Holdings, LLC (“SAN Holdings”), Sunday Seltzer, LLC (“Sunday Seltzer”) and Colombia-based beneficially owned subsidiary Hamsa Biochem SAS (“Hamsa”). The Company’s Annual Reportfiscal year is the 52-week or 53-week period that ends on Form 10-KMarch 31. The Company is a Maryland corporation established in 2005. The Company’s filings are available on www.sec.gov.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying condensed consolidated Balance Sheet as of December 31, 2021 and March 31, 2021, condensed consolidated statements of operations for the three and nine months ended December 31, 2021, and 2020, condensed consolidated statements of changes in stockholders’ deficit for the three and nine months ended December 31, 2021, and 2020, and condensed consolidated statements of cash flows for the nine months ended December 31, 2021, and 2020, are unaudited. The consolidated balance sheet as of March 31, 2021, which has been derived from audited financial statements, and these accompanying unaudited condensed consolidated financial statements (“interim statements”) of the Company have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (the “FASB”) within its Accounting Standards Codification (“ASC”) and under the rules and regulations of the Securities Exchange Commission (“SEC”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, and disclosures necessary for a fair presentation of these interim statements have been included. The results reported in these interim statements are not necessarily indicative of the results that may be reported for the entire year. These interim statements should be read in conjunction with the Company’s audited consolidated financial statements for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.


INDIA GLOBALIZATION CAPITAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(All amounts in USD, except number of shares)
  
Three months ended
December 31,
  
Nine months ended
December 31,
 
 2017  2016  2017  2016 
             
Revenues $762,009  $249,801  $1,050,582  $487,364 
Cost of revenues (excluding depreciation)  (723,062)  (121,829)  (893,113)  (276,418)
Selling, general and administrative expenses  (507,332)  (322,891)  (1,217,293)  (959,693)
Depreciation  (4,989)  (196,103)  (15,297)  (391,617)
Loss on investments/associates /joint ventures  -   4,910   -   (178,925)
Operating income /(loss) $(473,374) $(386,112) $(1,075,121) $(1,319,289)
Interest expense  (60,527)  (46,465)  (145,905)  (136,421)
Interest income & other income (net)  1,090   359,104   9,401   372,957 
Income before income taxes and minority interest attributable to non-controlling interest $(532,811) $(73,473) $(1,211,625) $(1,082,753)
Net income/(loss) $(532,811) $(73,473) $(1,211,625) $(1,082,753)
Non-controlling interests in earnings of subsidiaries  (230)  38,088   (634)  26,848 
Net income/(loss) attributable to common stockholders $(532,581) $(111,561) $(1,210,991) $(1,109,601)
Earnings/(loss) per share attributable to common stockholders:                
Basic $(0.02) $(0.00) $(0.04) $(0.04)
Diluted $(0.02) $(0.00) $(0.04) $(0.04)
Weighted-average number of common shares used in computing earnings per share amounts:                
Basic  28,169,292   27,446,095   27,126,208   27,446,095 
Diluted  28,169,292   27,446,095   27,126,208   27,446,095 

See accompanying Notes to Condensed Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements2021 (“Fiscal 2021”) contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.

INDIA GLOBALIZATION CAPITAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)
(Unaudited)

(All amountsFiscal 2021, specifically in USD, except number of shares and per share amounts)
  Three months ended December 31, 
  2017  2016 
  IGC  
Non-controlling
interest
  Total  IGC  
Non-controlling
interest
  Total 
Net income/(loss) $(532,581) $(230) $(532,811) $(111,561) $38,088  $(73,473)
Foreign currency translation adjustments  21,174   -   21,174   180,000   -   180,000 
Comprehensive income/(loss) $(511,407) $(230) $(511,637) $68,439  $38,088  $106,527 

  Nine months ended December 31, 
  2017  2016 
  IGC  
Non-controlling
interest
  Total  IGC  
Non-controlling
interest
  Total 
Net income/(loss) $(1,210,991) $(634) $(1,211,625) $(1,109,601) $26,848  $(1,082,753)
Foreign currency translation adjustments  10,252   -   10,252   128,150   -   128,150 
Comprehensive income/(loss) $(1,200,739) $(634) $(1,201,373) $(981,451) $26,848  $(954,603)

See accompanying Notes to Condensed Consolidated Financial Statements below in this report and the NotesNote 2 to the Audited Consolidated Financial Statements contained inconsolidated financial statements.

Principles of consolidation

The interim statements include the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.



INDIA GLOBALIZATION CAPITAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(All amounts in USD, except number of shares and per share amounts)
  Nine months ended December 31, 
  2017  2016 
Cash flows from operating activities:      
Net income (loss) $(1,211,625) $(1,082,753)
Adjustment to reconcile net income/(loss) to net cash:        
     Depreciation  15,297   391,617 
     Bad debts written off/creditors restated  24   - 
     Loss from Investments /joint venture /associates      178,925 
     Non-cash interest expenses  115,500   104,015 
     Stock base compensation and expense  426,111   - 
Changes in:        
    Accounts receivable $(401,811) $299,848 
    Other current assets  48,695   78,348 
    Trade payables  258,350   48,719 
    Other current liabilities  (223,877)  (501,787)
Net cash provided/(used) in operating activities $(973,336) $(483,068)
         
Cash flow from investing activities:        
         
   Purchase/addition of property, plant and equipment  (11,224)  (128,765)
   Proceeds from short term investment  (4,106)  (27,502)
   Deposit towards acquisition (net of cash acquired)  -   (114,427)
   Non-current assets  (286,167)  - 
Net cash provided/(used) by investing activities $(301,497) $(270,694)
         
Cash flows from financing activities:        
   Proceeds from share issue $2,636,478  $438,165 
   Net movement in short-term borrowing  -   (27,762)
   Proceeds /(repayment) from long-term borrowing  (452,080)  (910,583)
   Proceeds from loans  344,871   379,170 
   Expense for raising funds & issuance of stock  (111,253)  - 
Net cash provided/(used) by financing activities $2,418,016  $(121,010)
         
Effects of exchange rate changes on cash and cash equivalents  9,580   128,134 
Net increase/(decrease) in cash and cash equivalents  1,152,763   (746,638)
Cash and cash equivalent at the beginning of the period  538,029   1,490,693 
Cash and cash equivalent at the end of the period $1,690,792  $744,055 
         
Supplementary information:        
    Cash paid for interest $30,405  $32,406 
Non-cash items:        
   Common stock issued for interest payment on notes payable $115,500  $104,015 
   Common stock issued including ESOP, consultancy and other $465,158  $- 

See accompanying Notes to Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.


INDIA GLOBALIZATION CAPITAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1 – BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
a) Overview of India Globalization Capital, Inc. (“IGC”)
India Globalization Capital, Inc. (“IGC” or the “Company”), was incorporated in April 2005 under the lawsconsolidated accounts of the state of Maryland,Company and through its subsidiaries insubsidiaries. Intercompany accounts and transactions have been eliminated. In the USA, India, Hong Kong and Malaysia, is engaged in two major business segments - The first is a legacy infrastructure business consisting of heavy equipment rental, trading infrastructure related commodities, and real estate management. The second is development of cannabis-based combination therapies with a pipeline of products, including lead candidate, Hyalolex, designed to improve the lives of patients battling Alzheimer’s disease, Parkinson’s disease, chronic pain, post-traumatic stress disorder, and eating disorders and a long-term focus on developing blockchain technologies to solve critical issues facing the Cannabis industry.  
b) Changes in subsidiaries

IGC closed its Hong Kong based direct subsidiary IGC Clean Tech, and our India based subsidiary Techni Bharathi Private Limited (“TBL”), in the quarter ended December 31, 2017, beneficially incorporated as its Hong Kong based subsidiary IGC Enterprise that is involved in trading. TBL paid a premium of $745 for the 100% beneficial ownership.

c) Basis of presentation and use of estimates
The Company has prepared the accompanying unaudited Condensed Consolidated Financial Statements (“Financial Statements”) in accordance with the rules and regulationsopinion of the U.S. SecuritiesManagement, the interim statements reflect all adjustments, which are normal and Exchange Commission (“SEC”)recurring in nature, necessary for interimfair financial information.  Accordingly, they do not include allstatement presentation.

Use of the information and footnotes required by United States generally accepted accounting principles (“GAAP”) for complete financial statements.  In preparing theestimates

The preparation of financial statements in conformity with U.S. GAAP requires management is required to make estimates and assumptions that could affect the reported amounts reported in these condensed consolidatedof assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and accompanying notes.the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.  The results for interim periods do not necessarily indicate

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Management believes that the results that may be expected for any other interim period or forestimates and assumptions used in the full year. The significant accounting policies adopted bypreparation of the Company, in respect of these consolidated financial statements are set outprudent and reasonable. Significant estimates and assumptions are generally used for, but not limited to, allowance for uncollectible accounts receivable; sales returns; normal loss during production; future obligations under employee benefit plans; the useful lives of property, plant equipment; intangible assets; valuations; impairment of goodwill and investments; recoverability of advances; the valuation of options granted, and warrants issued; and income tax and deferred tax valuation allowances, if any. Actual results could differ from those estimates. Appropriate changes in estimates are made as Management becomes aware of changes in circumstances surrounding the estimates. Critical accounting estimates could change from period to period and could have a material impact on IGC’s results, operations, financial position, and cash flows. Changes in estimates are reflected in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017. Therefore, the Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and respective notes containedfinancial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been includedperiod in which changes are made and, if material, their effects are disclosed in the Financial Statements. Thenotes to the condensed consolidated financial statements include the accounts of the Companystatements.

Presentation and all its subsidiaries that are more than 50% owned and controlled. The Company consolidates the subsidiaries into its consolidated financial statements. Transactions between the Company and its subsidiaries have been eliminated in the consolidated financial statements.

d) Presentation offunctional currencies


In the quarter ended December 31, 2017, in addition to the US,

IGC operates in India, U.S., Colombia, and Hong Kong, and Malaysia and a substantial portion of the Company’s salesfinancials are denominated in USD, INR, and RM.the Indian Rupee (“INR”), the Hong Kong Dollar (“HKD”), or the Colombian Peso (“COP”). As a result, changes in the relative values of the U.S. dollar andDollar (“USD”), the INR, the HKD, or the RMCOP affect revenues and profits as the results are translated into U.S. dollars in the consolidated and pro formaour financial statements.

The accompanying financial statements are reported in U.S. dollars.USD. The INR, HKD, and the RMCOP are the functional currencies for certain subsidiaries of the Company. The translation of the functional currencies into U.S. dollars is performed for assets and liabilities using the exchange rates in effect at the balance sheet date and for revenues costs and expenses using average exchange rates prevailing during the reporting periods. Adjustments resulting from the translation of functional currency financial statements to reporting currency are accumulated and reported as other comprehensive income/(loss), a separate component of shareholders’ equity. Transactions in currencies other than the functional currency during the year are converted into the functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the consolidated statements of operations.

Impairment of long lived assets

e) Consolidation

The Company reviews its long-lived assets, with finite lives, for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable. Such circumstances include, though are not limited to, significant or sustained declines in revenues or earnings, future anticipated cash flows, business plans, and material adverse changes in the economic climate, such as changes in the operating environment, competitive information, and impact of changes in government policies. For assets that the Company intends to hold for use if the total of the expected future undiscounted cash flows produced by the assets or subsidiary company is less than the carrying amount of the assets, a loss is recognized for the difference between the fair value and carrying value of the assets. For assets, the Company intends to dispose of by sale, a loss is recognized for the amount by which the estimated fair value less cost to sell is less than the carrying value of the assets. Fair value is determined based on quoted market prices, if available, or other valuation techniques including discounted future net cash flows. Unlike goodwill, long-lived assets are assessed for impairment only where there are any specific indicators for impairment.


No impairment has been recorded for the nine months ended December 31, 2021, and 2020.

The

Short-term and long-term investments

Our policy for short-term and long-term investments is to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations, and delivers an appropriate yield in relation to our investment guidelines and market conditions. Short-term and long-term investments consist of corporate, various government agencies, and municipal debt securities, as well as certificates of deposit that have maturity dates that are greater than 90 days. Certificates of deposit and commercial paper are carried at cost which approximates fair value. Available-for-sale securities: Investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the statement of financial position.

Investments are initially measured at cost, which is the fair value of the consideration given for them, including transaction costs. Where the Company’s current fiscal year endsownership interest is more than 20% and the Company has a significant influence, the Company has accounted for the investment based on Marchthe equity method in accordance with ASC Topic 323, “Investments Equity Method and Joint Ventures”. Under the equity method, the Company’s share of the post-acquisition profits or losses of the equity investee is recognized in the consolidated statements of operations and its share of post-acquisition movements in accumulated other comprehensive income / (loss) is recognized in other comprehensive income / (loss). Where the Company does not have significant influence, the Company accounts for the investment in accordance with ASC Topic 321, “Investments-Equity Securities”.

As of December 31, 2018. Unless2021, the context requires otherwise, all referencesCompany does not have any investment in this report to “IGC,” “we,” “our” and “us” refer to India Globalization Capital, Inc., together with its subsidiaries, as listed and described in its Annual Report onmarketable securities.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-K filed with the SEC on July 14, 2017.  We exclude our investments and minority non-controlling interests, and any information provided by them is not incorporated by reference in this report, and you should not consider it a part of this report. Our filings are available on www.sec.gov. The information contained on our website, www.igcinc.us, is not incorporated by reference in this report, and you should not consider it a part of this report.10-Q

NOTE 2 – INTENTIONALLY LEFT BLANK

Stockbased compensation

NOTE 3 – ACCOUNTS RECEIVABLE

The Company accounts for stock-based compensation to employees and non-employees in conformity with the provisions of ASC Topic 718, “Stock-Based Compensation”. The Company expenses stock-based compensation over the requisite vesting period based on the estimated grant-date fair value of the awards. The Company accounts for forfeitures as they occur. Stock-based awards are recognized on a straight-line basis over the requisite vesting period. For stock-based compensation cost recognized at any date will be at least equal to the amount attributable to the share-based compensation that is vested at that date.


Compensation expense for the portion of the restricted stock units that contains a performance and market vesting condition is recognized over the derived service period based on the fair value of the awards on the grant date. Compensation expense for the portion of the restricted stock that contains performance and service vesting conditions is recognized over the requisite service period based on fair value of the awards on the grant date.

The Company estimates the fair value of stock option grants using the Black-Scholes option-pricing model and lattice model. The assumptions used in calculating the fair value of stock-based awards represent Management’s best estimates. Generally, the closing share price of the Company’s common stock on the date of grant is considered the fair value of the share. The volatility factor is determined based on the Company’s historical stock prices. The expected term represents the period that our stock-based awards are expected to be outstanding. The Company has never declared or paid any cash dividends.

Accounts receivable

We make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required. We had $164 thousand of accounts receivable, net of allowances, amounted to $1,155,229 and $752,926provision for the doubtful debt of $72 thousand as of December 31, 2017 and March 31, 2017, respectively.  The2021, as compared to $175 thousand of accounts receivable, net of reservesprovision for the quarterdoubtful debt of $63 thousand as of March 31, 2021.

Inventory

Inventory is valued at the lower of cost or net realizable value, which is defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.

Inventory consists of raw materials, finished goods related to wellness products, hand sanitizers, finished hemp-based products, beverages, among others as well as work-in-progress such as extracted crude oil, hemp-based isolate, growing crops, harvested crops, and herbal oils, among others. Work-in-progress also includes product manufacturing in process, costs of growing hemp, in accordance with applicable laws and regulations including but not limited to labor, utilities, fertilizers, and irrigation. Inventory is primarily accounted for using the weighted average cost method. Primary costs include raw materials, packaging, direct labor, overhead, shipping, and the depreciation of manufacturing equipment. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance, and property taxes.

Harvested crops are measured at net realizable value, with changes recognized in profit or loss only when the harvested crop:

- has a reliable, readily determinable, and realizable market value;

- has relatively insignificant and predictable costs of disposal; and

- is available for immediate delivery.

The Company believes its harvested crops do not have a readily available market. Hence, the Company values its harvested crops at cost. Please refer to Note 3 – “Inventory”, for further information.

Abnormal amounts of idle facility expense, freight, handling costs, scrap, discontinued products and wasted material (spoilage) are expensed in the period they are incurred.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Fair value of financial instruments

ASC 820, “Fair Value Measurement” defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. It also establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company’s financial instrument include cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair values due to the nature of the items. Please refer to Note 15 – “Fair Value of Financial Instruments”, for further information.

Loss per share

The computation of basic loss per share for the nine months ended December 31, 2017 come primarily2021, excludes potentially dilutive securities of approximately 6.2 million shares which includes share options, unvested shares such as restricted shares and restricted share units, granted to employees, non-employees and advisors, and shares from construction management,the conversion of outstanding units, if any because their inclusion would be anti-dilutive.

The weighted average number of shares outstanding for the nine months ended December 31, 2021, and 2020, used for the computation of basic earnings per share (“EPS”) is 49,643,942 and 40,915,196, respectively. Due to the loss incurred by the Company during the nine months ended December 31, 2021, and 2020, all the potential equity shares are anti-dilutive, and accordingly, the fully diluted EPS is equal to the basic EPS.

Cybersecurity

We have a cybersecurity policy in place and have taken cybersecurity measures that we expect are likely to safeguard the Company against breaches. In the nine months ended December 31, 2021, there were no impactful breaches in cybersecurity.

Intangible assets

The Company’s intangible assets are accounted for in accordance with ASC Topic 350, Intangibles Goodwill and Other. Intangible assets having indefinite lives are not amortized but instead are reviewed annually or more frequently if events or changes in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform an impairment analysis annually in the last month of the fiscal year on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18. Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine if the fair value is less than the carrying value of the intangible assets. If quantitative analysis is necessary, we would analyze various aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. The Company has analyzed a variety of factors in light of the known impact to date of the COVID-19 pandemic on its business to determine if a circumstance could trigger an impairment loss, and, at this time and based on the information presently known, does not believe it is more likely than not that an impairment loss has been incurred.

Intangible assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with ASC 360-10-35-21, definite lived intangibles are reviewed annually or more frequently if events or changes in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value.

The Company intends to capitalize trademarks and similar expenses exceeding $2,500 per trademark. Management may also capitalize trademarks and similar expenses up to $2,500 per trademark based on its potential and benefit in coming years.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Revenue Recognition

The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers (ASC 606). The core principle of this standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

ASC 606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales as follows:

I. Identify the contract with the customer.

II. Identify the contractual performance obligations.

III. Determine the amount of consideration/price for the transaction.

IV. Allocate the determined amount of consideration/price to the performance obligations.

V. Recognize revenue when or as the performing party satisfies performance obligations.

The consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the services and products in the Infrastructure and Life Sciences segment.

Revenue in the Infrastructure Business is recognized for the renting business when the equipment is rented, and terms of the agreement have been fulfilled during the period. The revenue from the purchase and resale of physical infrastructure commodities is recognized once the bill of lading along with the invoice has been transferred to the customer. Revenue from the execution of infrastructure contracts is recognized on the basis of the output method as and when part of the performance obligation has been completed and approval from the contracting agency has been obtained after a survey of the performance completion as of that date. In the Life Sciences segment, the revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer and the performance obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or, to the customer directly. Revenue from tolling services is recognized when the performance obligation, such as processing of the material, has been completed and output material has been transferred to the customer. We license our products to processors. The royalty income from licensing is recognized once goods have been sold by the processor to its customers.

Net sales disaggregated by significant products and services for the nine months ended December 31, 2021, and 2020 are as follows:

  

(in thousands)

Nine months ended December 31,

 
  

2021

($)
  

2020

($)
 

Infrastructure segment

        

Rental income (1)

  11   1 

Construction income (2)

  15   118 

Purchase and resale of physical commodities (3)

  -   - 
         

Life Sciences segment

        

Wellness and Lifestyle (4)

  227   664 

Tolling/White labeling service (5)

  22   34 

Total

  275   817 

(1) Rental income consists of income from rental of heavy construction equipmentequipment.

(2) Construction income consists of the execution of contracts directly or through subcontractors.

(3) Relates to the income from purchase and tradingresale of physical commodities used in commodities.infrastructure, like steel, wooden doors, marble, and tiles.

(4) Relates to revenue from wellness and lifestyle segment such as sale of hand sanitizer, bath bombs, lotion, gummies, beverages, textiles, hemp crude extract, hemp isolate, and hemp distillate and royalty income from the sale of Hyalolex™, now named Hyalolex™ Drops of Clarity™.

(5) Relates to income from tolling and white label services.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Leases

Lessor Accounting

Under the current ASU guidance, contract consideration will be allocated to its lease components and non-lease components (such as maintenance). For the Company as a lessor, any non-lease components will be accounted for under ASC Topic 606, “Revenue from Contracts with Customers”, unless the Company elects a lessor practical expedient to not separate the non-lease components from the associated lease component. The amendments in ASU 2018-11 also provide lessors with a practical expedient, by class of underlying asset, to not separate non-lease components from the associated lease component and, instead, to account for those components as a single component if the non-lease components otherwise would be accounted for under the new revenue guidance (“Topic 606”). To elect the practical expedient, the timing and pattern of transfer of the lease and non-lease components must be the same and the lease component must meet the criteria to be classified as an operating lease if accounted for separately. If these criteria are met, the single component will be accounted for under either Topic 842 or Topic 606 depending on which component(s) are predominant. The lessor practical expedient to not separate non-lease components from the associated component must be elected for all existing and new leases.

As lessor, the Company expects that post-adoption substantially all existing leases will have no change in the timing of revenue recognition until their expiration or termination. The Company expects to elect the lessor practical expedient to not separate non-lease components such as maintenance from the associated lease for all existing and new leases and to account for the combined component as a single lease component. The timing of revenue recognition is expected to be the same for most the Company’s new leases as compared to similar existing leases; however, certain categories of new leases could have different revenue recognition patterns as compared to similar existing leases.

For leases that are accounted for as operating leases, income is recognized on a straight-line basis over the term of the lease contract. Generally, when a lease is more than 180 days delinquent (where more than three monthly payments are owed), the lease is classified as being on nonaccrual and the Company stops recognizing leasing income on that date. Payments received on leases in nonaccrual status generally reduce the lease receivable. Leases on nonaccrual status remain classified as such until there is sustained payment performance that, in the Company’s judgment, would indicate that all contractual amounts will be collected in full.

Lessee Accounting

The Company adopted ASU 2016-02 effective April 1, 2019, using the modified retrospective approach. The standard establishes a right-of-use model (“ROU”) that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as a finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. In connection with the adoption, the Company will elect to utilize the modified retrospective presentation whereby the Company will continue to present prior period financial statements and disclosures under ASC Topic 840. In addition, the Company will elect the transition package of three practical expedients permitted within the standard, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. Further, the Company will adopt a short-term lease exception policy, permitting us to not apply the recognition requirements of this standard to short-term leases (i.e., leases with terms of 12 months or less), and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets.

Under ASU 2016-02 (Topic 842), lessees are required to recognize the following for all leases (with the exception of short-term leases) on the commencement date: (i) lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term.

At the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate for the same term as the underlying lease. The right-of-use asset is recognized initially at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. There was no impairment for right-of-use lease assets as of December 31, 2021.

The Company categorizes leases at their inception as either operating or finance leases. On certain lease agreements, the Company may receive rent holidays and other incentives. The Company recognizes lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays, which defer the commencement date of required payments. Please refer to “Note 9 - Leases”, for further information.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Recently issued accounting pronouncements

Accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its consolidated financial condition, results of operations, cash flows, or disclosures.

NOTE 3 INVENTORY

  

(in thousands)

 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Raw materials

  2,331   2,294 

Work-in-Progress

  2,208   2,199 

Finished goods

  889   985 

Total

  5,428   5,478 

Inventory in the form of work-in-progress as of December 31, 2021, is comprised of, but not limited to, harvested hemp crop hemp-based extracts, among others. Inventory also includes cost related to growing crops like seeds, fertilizer, other raw materials, labor, farm-related overheads, and the depreciation of farming equipment, hand sanitizers, gummies, lotions, beverages, and personal protection equipment, among others.

During the nine months ended December 31, 2021, inventory write down was approximately $22 thousand. Write downs are due to abnormal amounts of idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was recorded in Selling, General, and Administrative Expenses.

NOTE 4 OTHER CURRENT DEPOSITS AND NON-CURRENT ASSETSADVANCES


  

(in thousands)

 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Advances to suppliers and consultants

  1,044   1,295 

Advances for property, plant, and equipment

  -   4 

Other receivables and deposits

  511   1,741 

Prepaid expense and other current assets

  149   196 

Total

  1,704   3,236 

The Advances to suppliers and consultants primarily relate to advances to suppliers in our Life Sciences and Infrastructure segments. Advances for Property, Plant, and, Equipment include an advance paid for the equipment. Prepaid expensesexpense and other current assets consistinclude approximately $62 thousand of statutory advances as of December 31, 2021, as compared to $36 thousand as of March 31, 2021. Other receivables and deposits as of March 31, 2021, comprised an inventory of $1.7 million that was on deposit with a vendor. The vendor reported the following:

  
As of
December 31, 2017
  
As of
March 31, 2017
 
Prepaid /preliminary expenses $-  $6,750 
Advance to suppliers, others & services  355,490   352,850 
Security/statutory advances  17,320   14,216 
Prepaid and accrued interest  1,459   1,436 
Deposit and other current assets  5,516   35,156 
Total $379,785  $410,408 
Other non-current assets consist of the following:
  
As of
December 31, 2017
  
As of
March 31, 2017
 
Statutory/Other advances $521,631  $539,720 
Product formulation  299,282   - 
Total $820,913  $539,720 

On May 21, 2012, TBL entered intoinventory as stolen and filed an agreement with Weave & Weaveinsurance claim. The Company created a provision for the purchase of land. TBL gave Weave and Wave an advance of $383,832. As of$1.7 million inventory during the date of this filing,nine months ended December 31, 2021. We are simultaneously pursuing the parties are in the process of negotiating a settlement that includes the purchase and sale of land as well as the refund of the advance given by TBL.  Product Formulation is the capitalized part of expenses related to the formulation of products.  The products including, Hyalolex, our lead productvendor for patients suffering from Alzheimer’s are all non-FDA approved products.  These products do not require FDA approval for sale in dispensaries.compensation.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q
NOTE 5 – INTANGIBLE ASSETS AND GOODWILL
The movement in intangible assets and goodwill is given below.
  
As of
December 31, 2017
  
As of
March 31, 2017
 
Intangible assets at the beginning of the period $-  $113,321 
Amortization  -   (113,321)
Patent filings and rights  124,272   - 
Total Intangible assets $124,272  $- 
Goodwill of Cabaran Ultima Sdn Bhd  198,169   198,169 
Total Goodwill $198,169   198,169 
The value of goodwill for the two periods shown is $198,169 and is associated with the acquisition of Cabaran Ultima. The capitalized patent expenses are direct expenses, legal, filing fees etc., associated with filing patents in North America, Europe and Canada.

NOTE 5 INTANGIBLE ASSETS

Amortized intangible assets

 

(in thousands)

 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Patents

  286   220 

Other intangibles

  32   32 

Accumulated amortization

  (44)  (26

)

Total amortized intangible assets

  274   226 
         

Indefinite lived intangible assets

        

Patents

  152   181 

Other intangibles

  -   - 

Total unamortized intangible assets

  152   181 

Total intangible assets

  426   407 

The value of intangible assets includes the cost of acquiring patent rights, supporting data, and the expense associated with filing 13 patents. It also includes acquisition costs related to domains and licenses.

The amortization of patent and patent rights with finite life is up to 20 years, commencing from the date of grant or acquisition. The amortization expense in the three months ended December 31, 2021, and 2020, amounted to approximately $7 thousand and $4 thousand, respectively, whereas the amortization expense in the nine months ended December 31, 2021, and 2020, amounted to approximately $18 thousand and $10 thousand, respectively.

The Company regularly reviews its intangible assets to determine if any intangible asset is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period and concluded that, as of December 31, 2021, there was no impairment.

Estimated amortization expense

(in thousands)

($)

For the year ended 2022

22

For the year ended 2023

24

For the year ended 2024

27

For the year ended 2025

29

For the year ended 2026

32

NOTE 6 PROPERTY, PLANT AND EQUIPMENT


  

(in thousands, except useful life)

 
  

Useful Life (years)

  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Land

 N/A   4,602   4,606 

Buildings & facilities

 25   3,791   3,817 

Plant and machinery

 5-20   4,636   4,579 

Computer equipment

 3   229   216 

Office equipment

 3-5   156   111 

Furniture and fixtures

 5   133   130 

Vehicles

 5   165   165 

Construction in progress

 N/A   108   50 

Total gross value

     13,820   13,674 

Less: Accumulated depreciation

     (3,300)  (2,834

)

Total property, plant, and equipment, net

     10,520   10,840 

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

The depreciation expense in the three months ended December 31, 2021, and 2020, amounted to approximately $117 thousand and $124 thousand, respectively. The depreciation expense in the nine months ended December 31, 2021, and 2020, amounted to approximately $427 thousand and $302 thousand, respectively. The net decrease in total Property, plantPlant & Equipment is primarily due to depreciation and equipment consistforeign exchange translations. The net decrease in land is primarily due to foreign exchange translations because of a decline in the following: value of foreign currencies. The construction in progress relates to the Maryland office extension. For more information, please refer to Note 16 – Segment Information for the non-current assets other than financial instruments held in the country of domicile and foreign countries.

NOTE 7 INVESTMENTS IN NON-MARKETABLE SECURITIES


 Category Useful Life (years)  
As of
December 31, 2017
  
As of
March 31, 2017
 
Building (flat)  25  $245,035  $241,181 
Plant and machinery  20   1,737,381   1,710,055 
Computer equipment  3   160,643   157,349 
Office equipment  5   121,372   119,528 
Furniture and fixtures  5   72,167   70,368 
Vehicles  5   296,288   292,764 
Assets under construction  N/A   969,573   957,880 
Total     $3,602,459  $3,549,125 
Less: Accumulated depreciation     $(2,651,108) $(2,595,189)
Net Assets     $951,351  $953,936 

Short-term investment

Depreciation

(in thousands)

As of

December 31, 2021

($)

As of

March 31, 2021

($)

Investment in Evolve I (i)

-80

Total

-80

(i)

On May 12, 2020, the Company acquired an approximately 19.8% shareholding in Evolve I, Inc., a Washington corporation (“Evolve”) under the terms of a Share Subscription Agreement (“SSA”) for a consideration of approximately $249 thousand. However, based on an assessment of the business environment, the Company decided to dispose the holding and exit the acquisition. During the nine months ended December 31, 2021, the Company received back partial shares of IGC common stock, which had been given pursuant to the SSA, in exchange for the return of its shareholding in Evolve. Accordingly, the Company canceled the partial shares received by it and impaired its remaining investment of approximately $37 thousand.

Long-term investment

  

(in thousands)

 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Investment in equity shares of unlisted company

  11   12 

Total

  11   12 

The Company regularly reviews its investment portfolio to determine if any security is permanently impaired, which would require the Company to record an impairment charge in the period.

NOTE 8 CLAIMS AND ADVANCES

  

(in thousands)

 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Claims receivable (1)

  382   382 

Non-current deposits

  -   18 

Non-current advances (2)

  230   203 

Total

  612   603 

(1)

The claims receivable is due from the Cochin International Airport (“CIA”) which is partially owned by the State Government of Kerala. While the Company has initiated collection proceedings in the Commercial Court of Ernakulam, the Company believes it will be difficult to receive the amount in the next 12 months because of the time required for legal collection proceedings. The decrease in claims receivable was mainly due to foreign exchange translation as a result of a decrease in the value of the Indian Rupee.

(2)

Includes $200 thousand owed to one of our manufacturers for the purchase of equipment.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

NOTE 9 LEASES

The Company has short-term leases primarily consisting of spaces with the remaining lease term being less than or equal to 12 months. The total short-term lease expense and cash paid for the nine months ended December 31, 20172021, and 20162020 are approximately $131 thousand and $197 thousand, respectively. The Company also has four operating leases as of December 31, 2021.

America: In November 2019, the Company entered into a lease agreement with a lease term of less than 12 months. This lease was $15,297amended in March 2020, with a new lease term from March 1, 2020, to November 30, 2025. The annual lease expense is approximately $121 thousand. The lease contract does not contain any material residual value guarantees or material restrictive covenants. The remaining lease term for the operating lease is 3.9 years with a discount rate of 7%. The lease does not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate.

Asia: The Company renewed three lease agreements for terms between three to four years expiring between 2023 and $391,617 respectively.  Capital work-in-progress represents2024. The total annual lease expense is approximately $27 thousand. The lease contracts do not contain any material residual value guarantees or material restrictive covenants. The remaining lease term for the costoperating leases is between 2.25-3.00 years with a discount rate of property7%. The lease does not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate.

  

(in thousands)

Three months ended

December 31, 2021

($)

  

(in thousands)

Nine months ended

December 31, 2021

($)

 

Operating lease costs

  37   112 

Short term lease costs

  49   131 

Variable lease costs

  -   - 

Total lease costs

  86   243 

Right of use assets and equipment not put to use beforelease liabilities for our operating leases were recorded in the consolidated balance sheet date.as follows:


  

(in thousands)

  

(in thousands)

 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Assets

        

Operating lease asset

  482   488 

Total lease assets

  482   488 
         

Liabilities

        

Current liabilities:

        

Accrued liabilities and others (current portion – operating lease liability)

  120   90 

Noncurrent liabilities:

        

Operating lease liability (non-current portion – operating lease liability)

  374   405 

Total lease liability

  494   495 

NOTE 7 – INVESTMENTS – OTHERS

(in thousands)

As of

December 31, 2021

($)

Supplemental cash flow and non-cash information related to leases is as follows:

Cash paid for amounts included in the measurement of lease liabilities

–Operating cash flows from operating leases

80

Right-of-use assets obtained in exchange for operating lease obligations

482

Investments - others for each of the periods ended December 30, 2017 and March 31, 2017, consisted of the following:
  
As of
December 31, 2017
  
As of
March 31, 2017
 
Investment in equity shares of unlisted company & associates $67,912  $63,392 
Investment in affiliate  773,111   773,111 
Investment in land  5,174,611   5,174,611 
Total $6,015,634  $6,011,114 
Pursuant to the December 18, 2014 Purchase Agreement with Apogee, we issued 1,200,000 common shares of IGC valued at $888,000 for the purchase of 24.9% ownership interest in Midtown Partners & Co., LLC.  The Purchase Agreement expired on June 30, 2015, and the Company is pursuing its rights under the terms of the Purchase Agreement to recover certain damages. Value of investment in our books is $773,111 as onindiaglob20211231_10qimg002.jpg | December 31, 2017.2021, Form 10-Q

NOTE 8 – Intentionally left blank.

NOTE 9 – OTHER CURRENT AND NON-CURRENT LIABILITIES
Other current liabilities consist of the following:
   
As of
December 31, 2017
  
As
of March 31, 2017
 
Statutory payables $16,344  $15,203 
Employee related liabilities  457,757   676,511 
Total $474,101  $691,714 
For the quarter ended December 31, 2017, there were no other non-current liabilities.

As of December 31, 2021, the following table summarizes the maturity of our lease liabilities:

Dec-22

148

Dec-23

153

Dec-24

141

Dec-25

119

Dec-26

-

Less: Present value discount

(67)

Total lease liabilities

(494)

NOTE 10 RELATED PARTY TRANSACTIONS ACCRUED AND OTHER LIABILITIES

  

(in thousands)

 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

 

Compensation and other contributions

  457   849 

Provision for expenses

  205   309 

Other current liability

  257   430 

Total

  919   1,588 

As

Compensation and other contribution related liabilities consist of December 31, 2017, the Company has (i) a balance of $98,185 dueaccrued salaries to employees. Provision for expenses includes provision for legal, professional, and payable to our CEO inclusive of certain unpaid salaries from previous yearsmarketing expenses. Other current liability also includes $120 thousand and (ii) a secured loan at zero interest from spouse of our CEO in the amount of $244,412.

We pay an affiliate of our CEO $4,500 per month for office space and certain general and administrative services rendered in Maryland.  In addition, we pay another affiliate of our CEO $6,100 per month for office and facilities in Washington State.  We believe, based on rents and fees for similar services in the Washington, D.C. metropolitan area, and Washington State that the fee charged by the affiliates are at least as favorable as we could have obtained from an unaffiliated third party and these payments are not considered, or meant to be compensation to our CEO.  The rental agreement for the Maryland location is on a month-to-month basis and may be terminated by our Board of Directors$90 thousand of the Company at any time without notice. The rental agreement for Washington State facilities expired on December 31, 2017,current operating lease liability and it was renewed in January 2018 by mutual consent for 1 more year.  During the quarter ended December 31, 2017, the total rent paid to onestatutory payables of the affiliates for the office space (and services) in Maryland was $13,500. $36,600 is payable to one of the affiliates for the rental of the facilities in Washington State. As on December 31, 2017, an amount of $82,147 is due to RGF Cabaran’s director.  For December 31, 2017 there was no loan balance due to the Director of Cabaran.
Loans by Related Parties:
We have a secured working capital loan that has a loan balance of $195,061approximately $30 thousand and $24 thousand as of December 31, 20172021, and $97,500March 31, 2021, respectively.

NOTE 11 LOANS AND OTHER LIABILITIES

Forgiveness of Paycheck Protection Program Promissory Note:

On May 3, 2020, the Company signed the Paycheck Protection Program Promissory Note (the “PPP Note”) for a loan of approximately $430 thousand. The PPP Note was to mature after 2 years on May 3, 2022, with monthly repayments of approximately $18 thousand commencing November 1, 2020, and interest accrued on the outstanding principal balance at an annual fixed rate of 1.00%. On June 10, 2021, the Company received forgiveness for the full amount borrowed of approximately $430 thousand. This is accounted in the company’s condensed consolidated statements of operations and comprehensive loss for the nine months ended December 31, 2021, as other income, net.

Loan as of MarchDecember 31, 2017 from affiliates of our CEO,2021:

On June 11, 2020, the Company received an Economic Injury Disaster Loan (“EIDL”) for approximately $150 thousand at an annual interest rate of zero percent,3.75%. The Company must pay principal and interest payments of $731 every month beginning June 5, 2021. The SBA will apply each installment payment first to pay interest accrued to the day SBA receives the payment and will then apply any remaining balance to reduce principal. All remaining principal and accrued interest is due February 23, 2022.  There is no prepayment penalty.  The assetsand payable in 30 years from the date of the Company secureloan. For the loan.


Loans to Related Parties:
On April 30, 2015, FYE 2016, we loaned Apogee Financial Services, the majority owner of Midtown Partners, $70,000 as working capital for Midtown partners.  The loan is outstanding as of December 31, 2017.
NOTE 11 – NOTES PAYABLE AND LOANS – OTHERS
The Company has an unsecured Note Payable to Bricoleur Partners, L.P. in the amount of $1,800,000 (“2012 Security”).  Up to July 2014, the Company was making monthly payments of 17,100 shares of common stock.  Starting on August 2014, the Company started making a monthly payment of 23,489 shares of common stock.  Starting August 1, 2016, the Company started making a monthly payment of 30,000 shares.  The Company has never made a cash interest payment to Bricoleur on the Note.  The parties have agreed that the Company will make a payment (shown on our P&L under interest payment and not tax deductible to the Company) of 30,000 shares of common stock for each month the loan remains unpaid, regardless of the trading price of the stock.  The arrangement allows the Company and Bricoleur to pursue permanent conversion of the principal to common stock, or repayment of the principal using common stock. At the 2017 annual meeting of the shareholders the Company asked the shareholders to vote on allowing the Company to deliver up to an additional 2 million shares of our common stock as repayment of principal.  The vote on the amendment remains outstanding.  During the quarternine months ended December 31, 2017,2021, the Company issued a total of 90,000 shares valued at $48,000 to this debt holder, which constitutes non-tax-deductible paymentsinterest expense and principal payment for the Company.
EIDL was approximately $3.2 thousand and $2 thousand, respectively. As of December 31, 2017,2021, approximately $145 thousand of the Company has seven loans categorized as Loans Others totaling $737,097 at an average annual interest rate of 10%, as follows: Loan 1: We have a loan for $62,726, due on April 25, 2018 bearing 10% annual interest rate. This loan is from one of our Advisorsclassified as Long-term loans and former director. There is no prepayment penalty.  Loan 2: We have a secured loan from an individual for $100,000, at an annual interest rate of 24%, due February 23, 2022. There is no prepayment penalty. The assets of the Company secure the loan. Loan 3: We have a secured loan from an individual for $50,000, at an annual interest rate of 15%, due February 23, 2022. There is no prepayment penalty.  The assets of the Company secure the loan. Loan 4: We have a secured loan of $75,000 from an affiliate of our CEO, at an annual interest rate of 15%, due February 23, 2022.  There is no prepayment penalty.  The assets of the Company secure the loan. Loan 5: We have a secured loan that has a balanceapproximately $3 thousand as ofShort-term loans.

indiaglob20211231_10qimg002.jpg | December 31, 20172021, Form 10-Q

Other Liability:

  

(in thousands)

 
  

As of

 
  

December 31, 2021

($)

  

March 31, 2021

($)

 

Statutory reserve

  15   15 

Total

  15   15 

The statutory reserve is a gratuity reserve for employees in our CEO, at an annual interest rate of zero percent, due February 23, 2022. There is no prepayment penalty. The assets of the Company secure the loan. Loan 6: Secured loan from the spouse of our CEO,subsidiaries in the amount of $244,411. There is no prepayment penalty. The assets of the Company secure the loan. Loan 7: We have a working capital loan that has a loan balance as of December 31, 2017 of $9,899 from a relative of our CEO, at an annual interest rate of zero percent.India.

NOTE 12 COMMITMENTS AND CONTINGENCYCONTINGENCIES


No significant contingencies or commitments were made or existed during

The Company may be involved in legal proceedings, claims, and assessments arising in the three months endedordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the condensed consolidated financial statements as of December 31, 2017.


2021, except as disclosed below.

10

As of December 31, 2021, several law firms have filed shareholder lawsuits, two of which have been consolidated and remain pending, citing, among other things, the Company’s September 25, 2018, press release and the NYSE American delisting proceedings initiated in October 2018 (and overturned in February 2019) and subsequent fall in share price. The Company filed a motion to dismiss on October 11, 2019, which the court denied on January 29, 2021. As of October 20, 2021, the defendants in the shareholder action including the Company, have reached an agreement to settle the litigation, subject to final approval by the United States District Court for the District of Maryland (“Court”). A final settlement approval hearing has been scheduled for April 13, 2022, where the Court will consider, among other things, whether the settlement is fair, reasonable, and adequate, and whether the litigation should be dismissed on the merits and with prejudice. The Company has created a provision for $153 thousand as of December 31, 2021. For the current state of the consolidated Shareholder Class Action Litigation, please refer to Part II, Item 1 – Legal Proceedings.


Table

In the U.S., we provide health insurance, life insurance, and a 401(k) plan wherein the Company matches up to 6% of Contents
the employee’s pre-tax contribution up to a maximum annual amount determined by the IRS. In accordance with applicable Indian laws, the Company provides for gratuity, a defined benefit retirement plan (“Gratuity Plan”) covering certain categories of employees. The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee’s last drawn salary and the years of employment with the Company. In addition, employees receive benefits from a provident fund, a defined contribution plan. The employee and employer each make monthly contributions to the plan equal to 12% of the covered employee’s salary. The contribution is made to the Indian Government’s provident fund.


NOTE 13 COMMON STOCKSECURITIES

As of December 31, 2021, the Company was authorized to issue up to 150,000,000 shares of common stock, par value $0.0001 per share, and 51,054,017 shares of common stock were issued and outstanding. The Company is also authorized to issue up to 1,000,000 shares of preferred stock, par value $0.0001 per share, and no preferred shares were issued and outstanding as of December 31, 2021.

Our common stock tradesis listed on the NYSE AMERICAN under the symbol “IGC” with CUSIP number 45408X308, $0.0001 par value (“Common Stock”)American (ticker symbol: IGC). This security is also available for tradingtrades on the Borse Frankfurt, Stuttgart, and Berlin Exchangesstock exchanges (ticker symbol: IGS1). The Common stock of the Company is also available for trading on the Borse Frankfurt, Borse Berlin, and Borse Stuttgart (XETRA2) exchanges in Germany. The Warrants and Units now trade on the OTC Markets. We have redeemable Warrants (CUSIP number 45408X118 expiring on March 6, 2019) to purchase Common Stock (ticker symbol: IGC.WT) and Units consisting ofhas 91,472 units outstanding that can be separated into common stock. Ten units may be separated into one share of Common Stock and two redeemable warrants to purchase Common Stock that are not listed.common stock. The Unitunit holders are requested to contact the Company or our transfer agent, Continental Stock Transfer & Trust, to getseparate their existing Units separatedunits into Common Stockcommon stock.          

On January 13, 2021, the Company entered into a Sales Agreement (the “Agreement”) with The Benchmark Company, LLC (the “Sales Agent”) pursuant to which the Sales Agent is acting as the Company’s sales agent with respect to the issuance and Warrants.

As on December 31, 2017, there are 11,656,668 outstanding public warrantssale of up to purchase 1,165, 667 shares$75,000,000 of our common stock at an exercise price of $50.00 a share, expiring on March 6, 2019 and 831,768 private warrants to buy 83,176the Company’s shares of common stock, atpar value $0.0001 per share (the “Shares”), from time to time in an exercise price“at the market” (“ATM”) offering as defined in Rule 415(a)(4) of $9.0 that expired on December 8, 2017.
the Securities Act of 1933, as amended. During the quarternine months ended December 31, 2017,2021, the Company issued 90,000 penalty shares valued at $48,000 to Bricoleur Partners, L.P. forraised approximately $4.1 million of net proceeds from issuance of equity stock through the outstanding $1,800,000 promissory note (“2012 Security”).
On May 20, 2016, IGC entered into an At-The-Market Agency Agreement (“ATM Agreement”) with IFS Securities, Inc. (dba Brinson Patrick, a divisionoffering through the sale of IFS Securities, Inc.), as sales agent (“Brinson Patrick” or the “Agent”). Under this ATM agreement in the December quarter, 23,201 shares of IGC Common Stock, valued at $8,018, settled. This ATM agreement was terminated on September 30, 2017.

The Company entered into a new ATM agreement with The Benchmark Company and Joseph Gunnar as sales agents.  During the quarter ended December 31, 2017, the Company sold 1,381,317 shares of Common Stock valuated at $1,610,190 under this ATM agreement.

Under the December 18, 2014 Purchase Agreement with Apogee, we issued 1,200,000 common shares of IGC valued at $888,000 for the purchase of 24.9% ownership interest in Midtown Partners & Co., LLC.  Pending downward adjustments, subject to certain balance sheet items of MTP, a total of 500,000 shares of IGC common stock have been held back.  Pending the resolution of these balance sheet items, the shares that have been held back may be cancelled. The agreement had a deadline of June 30, 2015, for Apogee and Midtown Partners to obtain the requisite approvals from FINRA. Apogee did not file for approval on time, and consequently pursuant to the terms of the Agreement, there are several penalties that will apply, including the cancellation of 700,000 shares of IGC stock and a penalty of $125,000 owed by Apogee to us.  We are not seeking to consummate the acquisition of the remaining interest in Midtown Partners at this time.
The Company has granted (1) to its advisors and employees options to purchase a total of 650,0001.75 million shares of common stock at exercise prices ranging from $0.10stock. The Company may use these funds for working capital and capital expenditures, along with clinical trials, share repurchases, debt repayments, investments, including but not limited to, $0.60 are calculated with volatility 119%, interest rate 0.77%mutual funds, treasury bonds, cryptocurrencies, and expiration of 5 years, all of which are outstanding and exercisable as ofother asset classes.

indiaglob20211231_10qimg002.jpg | December 31, 2017; and (2) 100,000 shares to acquire the exclusive right to the license2021, Form 10-Q

NOTE 14 STOCK-BASED COMPENSATION


On April 1, 2009, the Company adopted ASC 718, “Compensation-Stock Compensation” (previously referred to as SFAS No. 123 (revised 2004), Share Based Payment).  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. 

As of December 31, 2017,2021, under both the Company’s previous 2008 and current 2018 Omnibus Plan, 4,374,899Incentive Plans, a total of 8,337,627 shares of common stock have been awarded.issued to employees, non-employees, and advisors. In addition, 5.9 million restricted share units (RSUs) fair valued at $6.96 million with a weighted average value of $1.19 per share, have been granted but not yet issued from different Incentive Plans and Grants. This includes 4 million RSUs granted to employees and directors, which consists of a vesting schedule based entirely on the attainment of both operational milestones (performance conditions) and market conditions, assuming continued employment either as an employee, or director with the Company. The performance based RSUs are accounted upon certification by the management confirming the probability of achievement of milestones. As of December 31, 2017, there are 650,000 stock2021, the management confirmed none of the milestones had been achieved but were considered probable to be achieved by March 31, 2027.

Additionally, options available to IGC’sheld by advisors and employees. Nodirectors to purchase 360 thousand shares of common stock underfair valued at $305 thousand with a weighted average of $0.85 per share, which have been granted but are to be issued over a vesting period, between Fiscal 2022 and Fiscal 2026. Options granted and issued before the 2008 ESOP planvesting period are available for future grants ofexpensed when issued.

The options or stock awards. In addition, inare valued using a Black-Scholes Pricing Model and Market based RSU are valued based on lattice model , with the quarter ended December 31, 2017 the shareholders approved 1,900,000 shares of common stock for award, at the discretion of the Board, as a special grantfollowing assumptions:

  

Granted in Fiscal 2022

  

Granted in Fiscal 2021

 

Expected life of options

 

5 years

  

5 years

 

Vested options

  100

%

  100

%

Risk free interest rate

  1.61

%

  0.68

%

Expected volatility

  281

%

  249

%

Expected dividend yield

 

Nil

  

Nil

 

The expense associated with share-based payments to employees, directors, advisors, and consultants. IGC granted 1,455,000 shares, out ofcontractors is allocated over the total approved byvesting or service period and recognized in the shareholders, to its directors and its employees with minimum vesting period of one year.


NOTE 15 – SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses were $507,332 for(including research and development). For the threenine months ended December 31, 2017 as compared to $322,891 for2021, the three months ended December 31, 2016.Company’s share-based expense and option-based expense shown in Selling, general and administrative expenses include compensation(including research and development) was $1.0 million and $24 thousand, respectively.

The expense associated with share-based payments to employees, directors, advisors, and contractors is allocated over the vesting or service period and recognized in the Selling, general and administrative expenses (including research and development). For the nine months ended December 31, 2020, the Company’s share-based expense and option-based expense shown in selling, general and administrative expenses (including research and development) was $459 thousand and $64 thousand, respectively.

Non-vested shares

 

Shares

(in thousands)

(#)

  

Weighted average

grant date fair value

($)

 

Non-vested shares as of March 31, 2021

  173   0.85 

Granted

  5,799   1.20 

Vested

  (114)  (1.15

)

Cancelled/forfeited

  (27)  (1.35

)

Non-vested shares as of December 31, 2021

  5,831   1.19 

Options

 

Shares

(in thousands)

(#)

  

Weighted average

grant date fair value

($)

  

Weighted average

exercise price

($)

 

Options outstanding as of March 31, 2021

  210   0.46   0.36 

Granted

  150   1.39   1.39 

Exercised

  -   -   - 

Cancelled/forfeited

  -   -   - 

Options outstanding as of December 31, 2021

  360   0.85   0.79 

There was a combined unrecognized expense of $6.2 million related to management, legalnon-vested shares and professional expenses, investor-relations expenses, acquisition related expenses and travel expenses.share options that the Company expects to be recognized over the weighted average life of 4.04 years.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

NOTE 16 15 IMPAIRMENT FAIR VALUE OF FINANCIAL INSTRUMENTS


None during fiscal quarter ended

As of December 31, 2017. 


NOTE 17 – INTEREST AND OTHER INCOME

Interest and other income for2021, the three-month periods ended December 31, 2017 and 2016 amounted to $1,090 and $359,104, respectively, and included income received from the supplyCompany’s marketable securities, if any, may consist of skilled operators for the heavy equipment rental business and from the rentliquid funds, which have been classified as Level 1 of the apartment belonging to TBL, which is in Kochi, India.

NOTE 18 – RECONCILIATION OF EPS
In accordance with ASC Topic 280 – "Earnings Per Share", the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional shares of common stock that wouldfair value hierarchy because they have been outstandingvalued using quoted prices in active markets. The Company’s cash and cash equivalents have also been classified as Level 1 on the same principle. Financial instruments are classified as current if they are expected to be liquidated within the potential common stock hadnext twelve months. The Company’s remaining investments have been issued and ifclassified as Level 3 instruments as there is little or no market data. Level 3 investments are valued using cost-method. For further information refer to Note 7, “Investments in Non-Marketable Securities.”

The following table presents information about the additional shares of common stock were dilutive.  Potential common stock consists of the incremental common stock issuable upon the exercise of common stock options and warrants (using the if-converted method). The computation of basic loss per share for the period ended December 31, 2017 excludes potentially dilutive securities of 1,815,667 shares underlying share purchase options and warrants, and 29,768 shares from the conversion of outstanding units because their inclusion would be antidilutive.

The historical weighted average per share for our shares through December 31, 2017, was applied using the treasury method of calculating the fully diluted shares.  The weighted average number of shares outstandingCompany’s assets that are measured at fair value on a recurring basis as of December 31, 2017 and 2016 used for the computation of basic earnings per share (“EPS”) is 28,169,292 and 27,446,095, respectively. Due to the loss incurred during the three-month period ended December 31, 2017, all the potential equity shares are anti-dilutive and accordingly, the fully diluted EPS is equal to the basic EPS.
NOTE 19 – INCOME TAXES

The Company adopted ASC 740, Accounting for Uncertainty in Income Taxes. In assessing the recoverability of its deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible. The management considers historical and projected future taxable income, and tax planning strategies in making this assessment.
The Company’s effective tax rate was 0% for both the quarters ended December 31, 2017 and 2016. The Company has US deferred tax assets, which have been offset by valuation allowance because of historical and expected losses.  As the Company reverses its losses and becomes profitable, we will reassess the likelihood of recovering a portion or all of the deferred tax assets.  
The Company recorded an income tax gain/expense of $0 resulting from operational results of its foreign entities for both three-month periods ended December 31, 2017 and 2016. As of December 31, 2017, and 2016, there was no significant liability for income tax associated with unrecognized tax benefits.  As of December 31, 2017, IGC could not use its net operating losses.
NOTE 20 – SEGMENT INFORMATION
Accounting pronouncements establish standards for the manner in which public companies report information about operating segments in annual and interim financial statements. Operating segments are components of an enterprise that have distinct financial information available and evaluated regularly by the chief operating decision-maker (“CODM”) to decide how to allocate resources and evaluate performance. The Company’s CODM is considered to be the Company’s chief executive officer (“CEO”). The CEO reviews financial information presented on an entity level basis for purposes of making operating decisions and assessing financial performance. The Company has determined that it operates as two operating and reportable segments: Pharmaceutical, and Legacy. Therefore, the Company has commenced reporting two segments.
Our legacy infrastructure business (“Legacy”, “Legacy Business””) that consists of trading, real-estate management, and heavy equipment leasing is one operating and reportable segment.  The other is the pharmaceutical segment that did not have revenue for the quarter ended December 31, 2017.

The following provides information required by ASC 280-10-50-38. Entity-Wide Information.

1) The table below shows revenue reported by product and service: 
  
Three months ended
December 31,
  
Nine months ended
December 31,
 
 2017  2016  2017  2016 
 Pharmaceutical Business
            
Revenue $-  $-  $-  $- 
Operating income/(Loss)  (422,706)  (243,917)  (957,870)  (711,950)
Net Profit/(Loss)  (483,054)  (285,592)  (1,103,372)  (838,774)
                 
Legacy Business                
Revenue $762,009  $249,801  $1,050,582  $487,364 
Operating income/(Loss)  (50,668)  (142,195)  (117,251)  (607,339)
Net profit/(Loss)  (49,527)  174,031   (107,619)  (270,827)

2(a) The following table presents revenue by geographic area as determined by where the customer is serviced:
  
Three months ended
December 31,
  
Nine months ended
December 31,
 
 2017  2016  2017  2016 
India $149,310  $(15,886) $382,580  $103,132 
Hong Kong  585,884   213,117   585,884   213,117 
Malaysia  26,815   52,570   82,118   171,115 
Total $762,009  $249,801  $1,050,582  $487,364 

In 2016 December Quarter, revenue of Techni Bharti Private Limited (IGC’s India- based subsidiary) is re-classified as other income.
2(b) The following table presents long-lived assets by geographic area:

 As of December, 30 
  2017  2016 
India $5,771,338  $5,790,817 
USA  2,090,978   3,334,509 
Malaysia  248,023   207,427 
Total $8,110,339  $9,332,753 
2(c) The table below shows nine-month revenue reported by product and service for the period ended December 31, 2017:
Product & Service Amount  % on total revenues 
       
Trading $874,099   83%
Real Estate $82,118   8%
Rental $94,365   9%
TOTAL $1,050,582   100%
NOTE 21 – CERTAIN AGED RECEIVABLES

The receivable and other assets as of December 31, 20172021, and March 31, 2017, include certain aged receivables in2021, and indicates the amount of $437,571. The aged receivables are due from the Cochin International Airport. Cochin International Airport is partially owned by the State Government of Kerala. The receivables have been due for periods in excess of one year as of December 31, 2017. These receivables are included in accounts receivable and have been classified as current because the arbitration process has concluded, and ruling was given in our favor. The Company continues to carry the fullfair value hierarchy of the receivables without interest and without any impairment, becausevaluation techniques the Company believes that there is minimal risk that this organization will become insolvent and unableused to make payment.determine such fair value:


(in thousands)

  

Level 1

($)

  

Level 2

($)

  

Level 3

($)

  

Total

($)

 

December 31, 2021

                
                 

Cash and cash equivalents:

  11,941   -   -   11,941 

Total cash and cash equivalents

  11,941   -   -   11,941 
                 

Investments:

                

-Marketable securities

  -   -   -   - 

-Non-marketable securities

  -   -   11   11 

Total Investments

  -   -   11   11 

  

Level 1

($)

  

Level 2

($)

  

Level 3

($)

  

Total

($)

 

March 31, 2021

                
                 

Cash and cash equivalents:

  14,548   -   -   14,548 

Total cash and cash equivalents

  14,548   -   -   14,548 
                 

Investments:

                

-Marketable securities

  -   -   -   - 

-Non-marketable securities

  -   -   92   92 

Total investments

  -   -   92   92 

NOTE 22 16 FAIR VALUE OF FINANCIAL INSTRUMENTS SEGMENT INFORMATION


FASB ASC 280, “Segment Reporting” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (“CODM”), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on our integration and Management strategies, we operate in 2 reportable segments: (i) Infrastructure segment and (ii) Life Sciences segment.

The fair valueCompany’s CODM is the Company’s chief executive officer (“CEO”). The CEO reviews financial information presented on an operating segment basis for purposes of making operating decisions and assessing financial performance. Therefore, and before our Life Sciences segment started, the Company determined that it operated in a single operating and reportable segment. As of the Company’s current assetsdate of this report and current liabilities approximate their carrying value becausein preparation for the new and different source of their short-term nature.  Such financial instruments are classified as currentrevenue, the Company has determined that it operates in 2 operating and are expected to be liquidated within the next twelve months.
reportable segments: (a) Infrastructure Business and (b) Life Sciences segment. The Company does not include intercompany transfers between segments for Management reporting purposes.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

The following provides information required by ASC 280-10-50-38 “Entity-wide Information”:

1) The table below shows revenue reported by segment:

Product & Service

  

(in thousands)

 

Segments

 

Nine months ended

December 31, 2021

($)

  

Percentage of

Total Revenue

(%)

 
         

Infrastructure segment

  26   10

%

Life Sciences segment

  249   90

%

Total

  275   100

%

  

(in thousands)

 

Segments

 

Nine months ended

December 31, 2020

($)

  

Percentage of

Total Revenue

(%)

 
         

Infrastructure segment

  119   15

%

Life Sciences segment

  698   85

%

Total

  817   100

%

For information for revenue by product and service, refer Note 2, “Summary of Significant Accounting Policies”.

2) The table below shows the revenue attributed to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the geographic location of customers:

    

(in thousands)

 

Segments

 

Country

 

Nine months ended

December 31, 2021

($)

  

Percentage of

Total Revenue

(%)

 
           

Asia

 

(1) India

  57   22

%

  

(2) Hong Kong

  -   -

%

America

 

U.S. and Colombia

  218   78

%

Total

  275   100

%

    

(in thousands)

 

Segments

 

Country

 

Nine months ended

December 31, 2020

($)

  

Percentage of

Total Revenue

(%)

 
           

Asia

 

(1) India

  119   15

%

  

(2) Hong Kong

  -   -

%

America

 

U.S. and Colombia

  698   85

%

Total

  817   100

%

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

3) The table below shows the non-current assets other than financial instruments held in the country of domicile and foreign countries.

  

(in thousands)

 

Nature of assets

 

USA

(Country of Domicile)

($)

  

Foreign Countries

(India, Hong Kong, and Colombia)

($)

  

Total as of

December 31, 2021

($)

 

Intangible assets, net

  426   -   426 

Property, plant and equipment, net

  5,913   4,607   10,520 

Non-marketable securities

  -   11   11 

Claims and advances

  212   400   612 

Operating lease asset

  420   62   482 

Total non-current assets

  6,971   5,080   12,051 

  

(in thousands)

 

Nature of assets

 

USA

(Country of Domicile)

($)

  

Foreign Countries

(India, Hong Kong, and Colombia)

($)

  

Total as of March 31, 2021

($)

 

Intangible assets, net

  407   -   407 

Property, plant and equipment, net

  6,228   4,612   10,840 

Non-marketable securities

  -   12   12 

Claims and advances

  200   403   603 

Operating lease asset

  488   -   488 

Total non-current assets

  7,323   5,027   12,350 

NOTE 17 SUBSEQUENT EVENTS

On January 18, 2022, the Board of Directors of the Company appointed former Congressman Jim Moran (“Congressman Moran”) to serve on the Board as a Class C director until the Company’s 2022 annual meeting of stockholders. Congressman Moran’s compensation will be consistent with the Company’s standard compensation for non-employee directors. As a new non-employee director, Congressman Moran was granted 150,000 Restricted Stock Units (“RSUs”) of the Company’s common stock. Of these, 50,000 RSUs vest immediately while the remaining 100,000 RSUs vest in equal annual instalments over two years.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Item 2. Management’sManagements Discussion and Analysis of Financial Condition and Results of Operations

The following discussionpurpose of this Management’s Discussion and analysisAnalysis (“MD&A”) is to provide an understanding of ourthe Company’s consolidated financial condition, and results of operations and cash flows, and should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the three months and the nine months ended December 31, 2021, and the Annual Report on Form 10-K filed withfor the SEC on July 14, 2017.  In addition to historical consolidated financial information, fiscal year ended March 31, 2021(the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs.  Our“2021 Form 10-K”). The Company’s actual results could differ materially from those discussed in the forward-looking statements.here. Factors that could cause or contribute to these differences include those discussed in the “Forward-Looking Statements” and “Risk Factors” sections, as well as discussed elsewhere in this report. The risks and uncertainties can cause actual results to differ significantly from those in our Annual Reportforward-looking statements or implied in historical results and trends. We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

Our primary source of revenue in the three months ended December 31, 2021, and December 31, 2020, was from our Life Sciences segment, which includes a biopharmaceutical component, and a wellness and lifestyle business, which involves:

(i)

development of potential new drugs, subject to applicable regulatory approvals, that use ultra-low doses of phytocannabinoids including cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), among others, in combination with other compounds, believed to assist in managing symptoms of diseases like Alzheimer’s,

(ii)

hand sanitizers and several hemp-based CBD products and brands, in various stages of development, for sale online and/or through stores,

(iii)

wholesale of hemp extracts including hemp crude extract, and hemp isolate, among others,

(iv)

white labeling of hemp-based products, and

(v)

the offering of tolling services like extraction and distillation to hemp-farmers and retailers.

(vi)Other hemp related lifestyle products

The Company’s second segment, the infrastructure segment, involves:

(i)

Execution of Construction Contracts – The Company is executing a road building contract in Kerala, India valued at approximately $1.2 million. Work on this project is sporadic based on COVID-19 restrictions. The Company intends to continue operations in this business line as the COVID-19 pandemic permits.

(ii)

Purchase and Resale of Physical Commodities Used in Infrastructure – This business line includes the purchase and resale of commodities, including steel, wooden doors, marble, and tiles, among others. This work has been adversely affected due to COVID-19. There was no revenue from this business line during the three months ended December 31, 2021, in part due to the COVID-19 pandemic. The Company intends to continue operations in this business line as the COVID-19 pandemic permits.

(iii)

Rental of Heavy Construction Equipment – We own heavy construction equipment such as motor grader and rollers, that we rent to construction contractors. This business is seasonal and had minimal revenue during the three months ended December 31, 2021, in part due to the COVID-19 pandemic. The Company intends to continue operations in this business line as the COVID-19 pandemic permits.

The Company operates both segments in compliance with applicable state, national, and local laws and regulations and only in locations and regions where it is legal to do so.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-K10-Q

Company Highlights

The Company completed all dose escalation studies, and, as announced by the Company on December 2, 2021, the results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA.

On October 28, 2021, the Company won Best CBD Topical award for its broad-spectrum hemp extract cream called Holi Wonder™ at the USA CBD Expo event held in Chicago, Illinois, U.S.

On October 5, 2021, the Company received a Good Manufacturing Practice (“GMP”) certification for its facilities in Vancouver, Washington, U.S. where it makes its products.

On September 17, 2021, the Company filed a provisional patent application with the USPTO for our IGC-513 for compositions and methods for treating patients with Dementia due to Alzheimer's disease.

During the nine months ended December 31, 2021, the Company raised approximately $4.1 million of net proceeds from the issuance of equity stock. The Company had entered an “at the market” (“ATM”) offering pursuant to the Sales Agreement (the “Agreement”) entered on January 13, 2021 with The Benchmark Company, LLC (the “Sales Agent”) for the issuance and sale of up to $75,000,000 of the Company’s shares of common stock, par value $0.0001 per share (the “Shares”).

The Company licenses a patent filing from the University of South Florida titled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease.” The U.S. Patent and Trademark Office (“USPTO”) issued a patent (#11,065,225) for this filing on July 20, 2021. The granted patent relates to IGC’s proprietary formulation, IGC-AD1, intended to assist in the treatment of individuals living with Alzheimer’s disease.

On June 10, 2021, the Company received forgiveness for the full amount borrowed as per the PPP Note of approximately $430 thousand.

Strategy

We have a two-pronged strategy for our Life Sciences biopharmaceutical component: the initial prong is to investigate IGC-AD1 for safety and efficacy in managing the symptoms of Alzheimer’s disease. This involves conducting Phase 1 through Phase 3 trials on IGC-AD1 over the next several years, subject to FDA regulatory approval and adequate funding, with the SEC on July 14, 2017, including the risk factors set out in Item 1A therein.  Therefore, the financial statements included in this Report should be read in conjunction with the audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K filed with the SEC on July 14, 2017.


Company Background

IGC has two linesanticipated goal of business.  The first isdemonstrating safety and efficacy and potentially obtaining FDA approval for IGC-AD1 as a legacy infrastructure business, which consists of heavy equipment rental, trading infrastructure related commodities, and real estate management.  The second is a cannabis pharmaceutical businessphytocannabinoid-based formulation that has developed a lead product, Hyalolex,can help manage some symptoms for treating patients diagnosed withsuffering from Alzheimer’s disease. The Company recently announcedsecond prong is to investigate the potential efficacy of IGC-AD1 on memory and on decreasing or managing plaques and tangles, some of the hallmarks of Alzheimer’s disease.

Our pipeline of investigational phytocannabinoid formulations also includes pain creams and tinctures for pain relief. We believe that the biopharmaceutical component of our Life Sciences strategy will take several years to implement and involves considerable risk; however, we believe it is working on using blockchainmay involve more significant defensible growth potential and first-to-market advantage.

Our consumer service and products strategy includes advancing the women’s line of products under the brand www.holief.com and developing and creating a cloud-based platform that connects women with health care professionals who can help with PMS and dysmenorrhea.

We believe that the additional investment in clinical trials, research, and development (“R&D”), facilities, marketing, and advertising, and the acquisition of products and businesses supporting our Life Sciences segment, are likely to address issues specificbe critical to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA),development and product origin assurance (POA).

Business Strategy

Our long-term goaldelivery of innovative products and positive patient and customer experiences. Part of our strategy is to establish IGC as a specialty-pharmaceutical provider of phytocannabinoid-based pharmaceuticalleverage our R&D and Complimentary Alternative Medicine (“CAM”, “nutraceutical”)our intellectual property to develop products that we believe are likely to be well-differentiated and -supported by science through planned pre-clinical and clinical trials. We believe this strategy has the potential to improve existing products and grow our trading in business in South Asia.  Our short-term goal islead to conduct humanthe creation of new products, which, based on scientific study and veterinarian medical trials on our four product candidates.  Our medium-term goal is to market CAM based therapies through joint venturesresearch, may offer positive results for the management of certain conditions, symptoms, and partnerships.side effects.

Business Organization

We are a Maryland corporation formed in April 2005.  In March 2006, we completed an initial public offering of our common stock.  Our principal office in the U.S. is in Bethesda Maryland, in addition we have a facility in Washington State. Our back office is located in Kochi, Kerala India. In addition, many of our staff and advisors work from their home offices. We maintain a website at http://www.igcinc.us, www.igcpharma.com and www.hyalolex.com and our telephone number is +1-301-983-0998. The information contained on our website is not incorporated by reference in this report, and you should not consider it a part of this report.  As ofindiaglob20211231_10qimg002.jpg | December 31, 2017, our operational subsidiaries are located in India, Hong Kong and Malaysia.  2021, Form 10-Q

COVID-19 Update

Our filings are available on www.sec.gov.


Products

Cannabinoids are chemical compounds that exert a range of effects on the body, including impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. Phytocannabinoids are cannabinoids that occur naturally in the cannabis plant, they are abundant in the viscous resin produced by glandular structures called trichomes. There are over 480 different compounds in the cannabis plant.  Many of them have been identified as cannabinoids. Of these THC (delta-9-tetrahydrocannabinol) is the main psychoactive component (“high”) in the plant with many therapeutic uses.  The other broadly pursued non-psychoactive phytocannabinoid, CBD (Cannabidiol), is pleiotropic influencing many pathways in humans, dogs, and cats and may be used to provide relief to a variety of symptoms including pain, seizures, and eating disorders.

The Company is focused on four products that it is preparing for pre-clinical trials: Natrinol is a natural substitute for Marinol, or synthetic THC. This product is aimed at relieving nausea, vomiting and increasing appetite in patients with AIDS and Cancer.  Caesafin uses combination therapy to alleviate seizures in dogs and cats.  Serosapse addresses several end points in Parkinson’s disease including Rapid Eye Movement (REM) sleep disorder, anxiety, and dyskinesia. Hyalolex is aimed at reducing the buildup of plaques, tangles and relieve several other end symptoms such as anxiety, sleep disorder and agitation in patients diagnosed with Alzheimer’s disease.  We expect to launch Hyalolex in select medical dispensaries in medical cannabis states in the U.S. in early 2018.

Services

The Company trades commodities, provides real estate management, and rents heavy equipment.  The heavy equipment rentalinfrastructure business is based in India.the state of Kerala, India, which is among the Indian states most affected by COVID-19, and Hong Kong with strict quarantine and travel restrictions. The commodity tradingrestrictions continue to adversely impact our infrastructure business, is basedfinancial condition, liquidity, and operations. While IGC remains committed to its Infrastructure business line and intends to continue pursuing the execution of construction contracts, the purchase and resale of physical commodities used in infrastructure, and the rental of heavy construction equipment as the pandemic allows, we have limited visibility into when economic conditions will recover in India and Hong Kong.  The real estate management business is based in Malaysia.  This business is our main sources of revenue. 

In each caseresponse, we have less than 1%oriented our current focus on a) the human trials on IGC-AD1 and getting an Alzheimer’s drug through trials and to market, subject to FDA approval, and b) launching a cannabinoid-based women’s wellness line of products designed to assist in managing PMS and Dysmenorrhea.

Results of Operations for the Three Months Ended

December 31, 2021, and December 31, 2020

The historical results presented below are not necessarily indicative of the market.



Patents, Development Pipeline, and Licenses

Although, the Company believes the registrationour results of patents is an important part of its business strategy and its success depends in part on such registration, the Company cannot guarantee that such patent filings will result in a successful registration with the USPTO.  Please see risk factors.

We have filed six provisional patents with the United States Patent and Trademark Office (“USPTO”), in the phytocannabinoid-based combination therapy space, for the indications of pain, medical refractory epilepsy, and cachexia. In addition, in May 2017, we acquired an exclusive license to a patent filed by the University of South Florida Research Foundation entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease”.  The table below provides a status of the patent filings:

IndicationProvisional FilingPCT FilingSubsequent Activity
Pain (IGC-501)9/16/149/16/15US National Case Filed – 6/15/16
Seizures (IGC-502)6/15/156/14/16US National Case Filed – 6/15/16
Seizures (IGC-503)4/1/154/1/16PCT Application Published- 10/6/16
Eating Disorders (IGC-504)8/12/158/11/16US and National Filing Anticipated 2/12/18
Seizures (IGC-505)6/15/166/15/16US National Filing Anticipated 12/15/18
Eating Disorders (IGC-506)2/28/17Anticipated- 2/28/18US and National Filing Anticipated 8/28/19
Alzheimer’s (IGC-AD1)7/30/2015Anticipated -2018US and National Filing Anticipated in 2018

For more in-depth information regarding our industry, products, services and corporate history, please refer to the Company’s Annual Report on Form 10-K filed with the SEC on July 14, 2017.

Results of Operations
Three Months ended December 31, 2017 Compared to Three Months ended December 31, 2016
Revenue - Total revenue was $762,009operations for the three months ended December 31, 20172021, and December 31, 2020:

Statement of Operations (in thousands, unaudited)

  

Three months ended December 31,

         
  

2021

($)
  

2020

($)
  

Change

($)
  

Percent

Change

 

Revenue

  142   108   34   31

%

Cost of revenue

  (80)  (94)  14   (15

)%

Gross profit

  62   14   48   343

%

Selling, general and administrative expenses

  (2,070)  (2,186)  116   (5

)%

Research and development expenses

  (377)  (154)  (223)  145

%

Operating loss

  (2,385)  (2,326)  (59)  3

%

Impairment of investment

  -   -   -   -

%

Other income, net

  4   3   1   33

%

Loss before income taxes

  (2,381)  (2,323)  (58)  2

%

Net loss

  (2,381)  (2,323)  (58)  2

%

Revenue – Revenue in the quarter ended December 31, 2021, and December 31, 2020, was primarily derived from our Life Sciences segment, which involved sales of products such as compared to $249,801lotion, gummies, and alcohol-based hand sanitizers, among others. Revenue was approximately $142 thousand and $108 thousand for the three months ended December 31, 2016.  In2021, and December 31, 2020, respectively.

Revenue in the three-month periodLife Sciences segment in the three months ended December 31, 2016, the revenue consisted of trading, real estate management, and rental of heavy equipment. The increase in revenue during the same period in 2017 is from an increase2020, was $56 thousand as compared to $134 thousand in the volume and underlining commodity involvedthree months ended December 31, 2021, albeit with a change in the trading.  In December 2016 most of the revenue came from trading electronics andproduct mix. Revenue in 2017 from trading commodities related to infrastructure.

Cost of Revenue (excluding depreciation) – Cost of revenueour Infrastructure segment for the three months ended December 31, 20172020, was $723,062 as$52 thousand compared to $121,829$8 thousand in the three months ended December 31, 2021. The revenue relates to the execution of a construction contract. Primarily due to COVID-19, we have limited visibility on when either of our segments will stabilize, generate significant revenue, and become predictable. We expect volatility in both segments in the foreseeable future. We expect to be opportunistic in providing personal protection equipment, including hand sanitizers, as areas reopen from the pandemic.

Cost of revenue – Cost of revenue amounted to approximately $80 thousand for the three months ended December 31, 2016.2021, compared to $94 thousand in the three months ended December 31, 2020. The increase in cost of revenue stems from an increase in the volumethree months ended December 31, 2021, is primarily attributable to raw materials that are required to produce our products.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Selling, General and Administrative -

Selling, general and administrative expenses were $507,332 (“SG&A”)– SG&A expenses consist primarily of employee-related expenses, sales commission, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any. SG&A expenses decreased by approximately $116 thousand or 5% to approximately $2.07 million for the three months ended December 31, 2017 as compared to $322,8912021, from approximately $2.19 million for the three months ended December 31, 2016.  Most2020. The decrease of the expenses are public-company related expenses, including legal fees.

Depreciation – The depreciation expense was approximately $4,989 in$116 thousand consists of one-time $245 thousand inventory-related adjustments during the three months ended December 31, 2017 as compared2020.

Research and Development expenses– Research and Development (“R&D”) expenses were attributed to $196,103conducting the Phase 1 trial on patients suffering from Alzheimer’s disease and product research in the three months ended December 31, 2016.our Life Sciences segment. The decrease in depreciation is from the curtailment of the iron-ore mining business in China.


Interest and other financial expenses – The interest expense and other financialR&D expenses for the three months ended December 31, 2017 were2021, are approximately $60,527 as$377 thousand compared to approximately $46,465$154 thousand for the three months ended December 31, 2016.  Most2020, increase of approximately $223 thousand or 145%. The cost associated with this work is mostly associated with the clinical trial on patients suffering from Alzheimer’s disease, research comprising of plant extracts that could be productized and data to support the efficacy of the interestextracts, product research, designing, formulating and market analysis. Of the increase of $223 thousand, $100 thousand is paidattributed to one-off expense related to the completion of Phase 1 clinical trial and $50 thousand to one-off expense related to the grant of licensed patent from the University of South Florida. We expect R&D expenses to increase with common shares of the Company and is therefore non-cash.
Interest Income and Other income/(loss) – Interest income and other income was $1,090 for the three-month period ended December 31, 2017 as comparedprogression in trials on IGC-AD1, subject to $359,104 in December 31, 2016. FDA approval.

Other income, includes the rent of apartment ownednet –Other net income increased by one of the subsidiaries and the income by supply of skilled operators for the heavy equipment rental business.


Consolidated Net Income/(loss) – Inapproximately $1 thousand or 33% during the three months ended December 31, 2017, the Company reported a GAAP net loss of $532,581 and a GAAP EPS loss of $0.02 compared to a GAAP net loss of $111,561 and a GAAP EPS loss of $0.002021. The total other income for the three months ended December 31, 2016.   

2021, and 2020 was approximately $4 thousand and $3 thousand, respectively. Other income includes interest income and rental income, among others.

15


Operations for the Nine Months ended Ended

December 31, 2017 Compared to Nine Months ended2021, and December 31, 20162020

Revenue - Total revenue was $1,050,582

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the nine months ended December 31, 20172021 and December 31, 2020:

Statement of Operations (in thousands, unaudited)

  

Nine months ended December 31,

         
  

2021

($)
  

2020

($)
  

Change

($)
  

Percent

Change

 

Revenue

  275   817   (542)  (66

)%

Cost of revenue

  (149)  (731

)

  582   (80

)%

Gross profit

  126   86   40   47

%

Selling, general and administrative expenses

  (7,956)  (5,424

)

  (2,532)  47

%

Research and development expenses

  (1,097)  (595

)

  (502)  84

%

Operating loss

  (8,927)  (5,933

)

  (2,994)  50

%

Impairment of investment  (37)  -   -   -%

Other income, net

  451   71   380   535

%

Loss before income taxes

  (8,513)  (5,862

)

  (2,651)  45

%

Net loss

  (8,513)  (5,862

)

  (2,651)  45

%

Revenue – Revenue in the nine months ended December 31, 2021, was primarily derived from our Life Sciences segment, which involved sales of products such as compared to $487,364lotion, gummies, and alcohol-based hand sanitizers, among others. Revenue was approximately $275 thousand and $817 thousand for the nine months ended December 31, 2016.  In2021, and the nine-month periodnine months ended December 31, 2016, the revenue consisted2020, respectively.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Revenue in the volume of business.


Cost ofLife Sciences segment in the nine months ended December 31, 2020, was $698 thousand as compared to $249 thousand in the nine months ended December 31, 2021, albeit with a change in product mix. Revenue (excluding depreciation) – Cost of revenuein our Infrastructure segment for the nine months ended December 31, 20172020, and December 31, 2021, was $893,113$119 thousand and $26 thousand, respectively. Such revenue relates to execution of a construction contract. Primarily due to COVID-19, we have limited visibility on when either of our segments will stabilize, generate significant revenue, and become predictable. We expect volatility in both segments in the foreseeable future. We expect to be opportunistic in providing personal protection equipment, including hand sanitizers, as comparedthe country reopens from the pandemic.

Cost of revenue – Cost of revenue amounted to $276,418approximately $149 thousand for the nine months ended December 31, 2016.2021, compared to $731 thousand in the nine months ended December 31, 2020. The increase in cost of revenue stems from an increase in the volume of business as reflected in the increase in revenuenine months ended December 31, 2021, is primarily attributable to raw materials required to produce our products.

Selling, general and is related to the trading, real estate and rental business.


Selling, General and Administrative -administrative expenses Selling, general and administrative expenses were $1,217,293consist primarily of employee-related expenses, sales commission, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation and write-offs relating to doubtful accounts and advances, if any. Selling, general and administrative expenses increased by approximately $2.5 million or 47% to approximately $7.96 million for the nine months ended December 31, 2017 as compared to $959,6932021, from approximately $5.4 million for the nine months ended December 31, 2016.  Most of2020.

The $2.5 million increase in Selling, general & administrative expenses is attributable to the expenses are public-companyfollowing: approximately $1.7 million to a provision for stolen inventory at our vendor’s premises, approximately $172 thousand to investor relations related expenses, including legal fees.approximately $125 thousand for an IRS tax penalty, and non-cash increase of $499 thousand and $125 thousand for to Common stock-based compensation and depreciation expenses, respectively.

Depreciation

Research and Development expenses Research and Development expenses were attributed to conducting the Phase 1 trial on patients suffering from Alzheimer’s disease and product research in our Life Sciences segment. The depreciation expense was approximately $15,297 in the nine months ended December 31, 2017 as compared to $391,617 in the nine months ended December 31, 2016.  The decrease in depreciation is from the curtailment of the iron-ore mining business in China.


InterestResearch and other financial expenses – The interest expense and other financialDevelopment expenses for the nine months ended December 31, 2017 were2021, are approximately $145,905 as$1.1 million compared to approximately $136,421$595 thousand for the nine months ended December 31, 2016.  Most2020. The cost associated with this work is mostly associated with the clinical trial on patients suffering from Alzheimer’s disease, research comprising of plant extracts that could be productized and data to support the efficacy of the interestextracts, product research, designing, formulating and market analysis. Of the increase of $502 thousand, $100 thousand is paidattributed to one-off expense related to completion of Phase 1 clinical trial and $50 thousand to one-off expense related to the grant of licensed patent from University of South Florida. We expect Research and Development expenses to increase with common sharesprogression in trials on IGC-AD1.

Impairment of investment – On May 12, 2020, the Company acquired approximately 19.8% shareholding in Evolve I, Inc. However, based on an assessment of the business environment, the Company decided to dispose the holding and is therefore non-cash.

Interest Income and Other income/(loss) – Interest income and other income was $9,401 forexit the nine-month periodacquisition. During the nine-months ended December 31, 2017 as compared2021, the Company received back partial shares of IGC common stock, which had been given pursuant to $372,957the SSA, in December 31, 2016. exchange for the return of its shareholding in Evolve. Accordingly, the Company cancelled the partial shares received by it and impaired its remaining investment of approximately $37 thousand.

Other income, includes the rent of apartment ownednet – Other net income increased by one of the subsidiaries and the income by supply of skilled operators for the heavy equipment rental business.


Consolidated Net Income/(loss) – Inapproximately $380 thousand during the nine months ended December 31, 2017, the Company reported a GAAP net2021. The total other income loss of $1,210,991 and a GAAP EPS loss of $0.04 compared to a GAAP net income loss of $1,109,601 and a GAAP EPS loss of $0.04 for the nine months ended December 31, 2016.   
Off-Balance Sheet Arrangements

We do not have any undisclosed investments in special purpose entities or undisclosed borrowings or debt.
Liquidity2021, and Capital Resources
This liquidity2020 is approximately $451 thousand and capital resources discussion compares the consolidated company financial position for the nine-month periods ended December 31, 2017 and 2016.
$71 thousand, respectively. Other income includes interest income, rental income, among others. During the nine months ended December 31, 2017,2021, the other income included approximately $430 thousand related to forgiveness of the PPP Note.

Liquidity and Capital Resources

Our sources of liquidity are cash usedand cash equivalents, funds raised through the ATM offering, cash flows from operations, short-term and long-term borrowings, and short-term liquidity arrangements. The Company continues to evaluate various financing sources and options to raise working capital to help fund current research and development programs and operations. The Company does not have any material long-term debt, capital lease obligations or other long-term liabilities, except as disclosed in operating activities was $973,336 comparedthis report. Please refer to $483,068 used duringNote 12, “Commitments and contingencies”, Note 11, “Loans and Other Liabilities” and Note 9, “Leases” in Item 1 of this report for further information on Company commitments and contractual obligations.

While the Company believes its existing balances of cash, cash equivalents and marketable securities and other short-term liquidity arrangements will be sufficient to satisfy its working capital needs, capital asset purchases, debt repayments, investments, including but not limited to, mutual funds, treasury bonds, cryptocurrencies, and other asset classes, clinical trials and other liquidity requirements, if any, associated with its existing operations over the next 12 months, it will raise money as and when it is able to do so. The Company continues to utilize the ATM to raise capital. Management is actively monitoring the impact of COVID-19 on the Company’s financial condition, liquidity, operations, suppliers, industry, legal expenses, and workforce.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Please refer to Item 1A. “Risk Factors” for further information on the risks related to the Company.

  

(in thousands, unaudited)

         
                 
  

As of

December 31, 2021

($)

  

As of

March 31, 2021

($)

  

Change

  

Percent Change

 

Cash and cash equivalents

  11,941   14,548   (2,607)  (18

)%

Working capital

  17,958   21,149   (3,191)  (15

)%

Cash and cash equivalents

Cash and cash equivalents decreased by approximately $2.6 million to $11.9 million in the nine months ended December 31, 2016.2021, from $14.5 million as of March 31, 2021, a decrease of approximately 18%.

The major decrease was due to approximately $152 thousand in purchase of property, plant, and equipment and a net cash loss of approximately $5.6 million, part of which was set-off with approximately $4.1 million of net proceeds from the issuance of equity stock through an ATM offering.

During

Summary of Cash flows

  

(in thousands, unaudited)

         
                 
  

Nine months ended December 31,

         
  

2021

  

2020

  

Change

  

Percent Change

 

Cash used in operating activities

  (6,574)  (8,295)  1,721   (21

)%

Cash (used in)/ provided by investing activities

  (189)  1,459   (1,648)  (113

)%

Cash provided by financing activities

  4,143   530   3,613   682

%

Effects of exchange rate changes on cash and cash equivalents

  13   16   (3)  (19

)%

Net decrease in cash and cash equivalents

  (2,607)  (6,290)  3,683   (59)%

Cash and cash equivalents at the beginning of period

  14,548   7,258   7,290   100

%

Cash and cash equivalents at the end of the period

  11,941   968   10,973   1,134

%

Operating Activities

Net cash used in operating activities for the nine months ended December 31, 2017, $301,4972021, was approximately $6.6 million. This consists of a net loss of approximately $8.5 million and non-cash items totaling approximately $2.89 million, which in turn consist of an amortization/depreciation charge of approximately $486 thousand, stock-based expenses totaling approximately $1.1 million, approximately $1.7 million for a provision related to stolen inventory, approximately $37 thousand related to impairment of investment and gain due to forgiveness of the PPP Note of approximately $430 thousand. Changes in operating assets and liabilities had a net negative impact of approximately $944 thousand on cash, of which approximately $51 thousand is related to inventory.

Net cash used in operating activities for the nine months ended December 31, 2020, was approximately $8.3 million. This consists of a net loss of approximately $5.9 million and non-cash items totaling approximately $835 thousand, which in turn consist of an amortization/depreciation charge of approximately $312 thousand and stock-based expenses totaling approximately $523 thousand. Changes in operating assets and liabilities had a negative impact of approximately $3.3 million on cash, of which approximately $911 thousand was due to an investment in inventory.

Investing Activities

Net cash used in investing activities from continuing operations as compared to $270,694 used duringfor the same period in 2016.

For the quarternine months ended December 31, 2017, our non-GAAP cash burn2021, was approximately $360,279 after adjusting$189 thousand, which is comprised of expenses of approximately $37 thousand for $4,989the acquisition and filing expenses related to patents and purchase of depreciation, $48,000property, plant, and equipment of non-cash interest expenses and $119,313 for ESOP expenses.approximately $152 thousand.


 At the end ofindiaglob20211231_10qimg002.jpg | December 31, 2017, our2021, Form 10-Q

Net cash provided by investing activities for the nine months ended December 31, 2020, was $1.5 million, which is comprised of approximately $92 thousand for the acquisition and filing expenses related to patents and trademarks, purchase of property, plant, and equipment of $1.4 million and investments of approximately $149 thousand in non-marketable securities and proceeds of $3 million in marketable securities.

Financing Activities

Net cash equivalents alongprovided by financing activities was approximately $4.1 million for the nine months ended December 31, 2021, which is comprised of net proceeds from issuance of equity stock through ATM offering, net of all expenses related to issuance of stock.

Net cash provided by financing activities was $530 thousand for the nine months ended December 31, 2020, which is comprised of proceeds from loans.

Off-Balance Sheet Arrangements

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions or foreign currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit support to us or that engages in leasing, hedging or research and development services with restricted cash was $1,690,792 and working capital of $1,901,623. We currently have sufficient cash to further our patent portfolio, testing and commence marketing and licensing our Alzheimer’s product, one of the Company’s four cannabis-related medical products.us.

Critical Accounting Policies


While all accounting policies impact the financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require management’sManagement’s most subjective or complex judgments and estimates. Our managementManagement believes the policies that fall within this category are the policies on revenue recognition, accounting forinventory, accounts receivable, foreign currency translation, impairment of long-lived assets and investments, stock-based compensation, goodwill, and income taxes.


cybersecurity. We have a cybersecurity policy in place and have taken cybersecurity measures that we expect are likely to safeguard the Company against breaches. There were no impactful breaches in cybersecurity during the nine months ended December 31, 2021.

16


Please see our disclosures onin Note 2 - Summary of Significant Accounting Policies ofto the Notes to the unauditedUnaudited Condensed Consolidated Financial Statements in this report, in the Notes to the Audited Consolidated Financial Statements in the 2021 Form 10-K, as well as Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations in the 2021 Form 10-K, for a discussion of all our critical and significant accounting policies.

Recent Accounting Pronouncements

The recent accounting pronouncements are discussed in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report and Note 2 - Significant Accounting Policies ofin the Notes to the auditedAudited Consolidated Financial Statements in Part II of our Annual Report on2021 Form 10-K, filed with the SEC on July 14, 2017 for a discussion10-K.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Forward-Looking Statements and Important Factors
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements.  This report and the documents incorporated in this report by reference contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Additionally, we, or our representatives may, from time to time, make other written or verbal forward-looking statements and discuss plans, expectations and objectives regarding our business, financial condition and results of operations.  Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as “believe,” “project,” “expect,” “trend,” “estimate,” “forecast,” “assume,” “intend,” “plan,” “target,” “anticipate,” “outlook,” “preliminary,” “will likely result,” “will continue” and variations of them and similar terms are intended to be “forward-looking statements” as defined by federal securities laws. We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans and projections. Forward-looking statements are based upon certain assumptions and subject to risks and uncertainties, including those identified in the “Risk Factors” included in our annual report on Form 10-K for the fiscal year ending March 31, 2017, filed with the SEC on July 14, 2017, and in the documents incorporated by reference that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made.  Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Pursuant

Item 3 does not apply to Item 305(e) of Regulation S-K, the Company is not required to provide the information required by this Item as it isus because we are a “smallersmaller reporting company.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures


Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to Management, including our Chief Executive Officer (our principal executive officer) and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

As

Our Management, including the Chief Executive Officer and Principal Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report, management conducted anreport. Based on this evaluation, under the supervision and with the participation of itsour Chief Executive Officer (CEO) and its principal financial and accounting officer (PFAO), of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934.  Based upon that evaluation, our CEO and PFAOPrincipal Financial Officer concluded that our disclosure controls and procedures arewere effective to ensure that the information required to be disclosed in the reports filed or submitted by the Company in reportsus under the Exchange Act iswas recorded, processed, summarized and reported within the requisite time periods specified in the SEC rules and forms; andthat such information was accumulated and communicated to the Company’s management,our Management, including its principal executive officerour Chief Executive Officer and principal financial officer,Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.


Changes in Internal Control over Financial Reporting


There were no

Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal controlscontrol over financial reporting occurred during our fiscal quarterthe three months ended December 31, 2017 which were identified in conjunction with Management’s evaluation required by paragraph (d) of Rule 13a-15 and 15d-15 under the Exchange Act2021, that have materially affected, or are reasonably likely to materially affect, our internal controlscontrol over financial reporting.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q
Limitations on the Effectiveness of Disclosure Controls and Procedures
Our management, including our CEO and PFAO, do not expect that our internal control over financial reporting will prevent all errors and all fraud.  Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.  Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.



PART II OTHER INFORMATION

Item 1. Legal Proceedings


There are no material

The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

As of December 31, 2021, the Company and one of its officers are parties to the following litigation matters:

Apogee Financial Investments, Inc., et al. v. India Globalization Capital, Inc., et al., Civil Action No. 1:21-cv-03809 (U.S. District Court for the Southern District of New York). On April 29, 2021, Apogee Financial Investments, Inc. (“Apogee”) and John R. Clarke (“Clarke”) filed a complaint against the Company.Company and IGC’s President and Chief Executive Officer, Ram Mukunda (“Mukunda”) (the “Apogee Litigation”). The litigation was originally initiated by IGC on February 8, 2021 (India Globalization Capital, Inc. v. Apogee Financial Investments, Inc., Civil Action No. 1:21-cv-01131, U.S. District Court for the Southern District of New York), wherein IGC alleged that Apogee breached a purchase agreement dated December 18, 2014 related to IGC’s intended purchase of a business known as Midtown Partners & Co., LLC (“Midtown”). In response to the original lawsuit filed by IGC, Apogee and Clarke filed a counterclaim as well as the Apogee Litigation. On May 21, 2021, IGC and Mukunda filed a partial motion to dismiss both the counterclaim and the Apogee Litigation. Before the Court ruled on the motion to dismiss, on June 28, 2021, Apogee and Clarke filed an amended complaint claiming that IGC and Mukunda fraudulently induced Apogee into entering the purchase agreement for the sale of Midtown and breached the purchase agreement. Apogee and Clarke also seek a declaratory judgment and indemnification for certain alleged losses they claim to have suffered. Finally, Clarke claims that he is entitled to shares of IGC common stock as wages. On July 23, 2021, IGC and Mukunda again moved to partially dismiss the counterclaim and the Apogee Litigation. The motion to dismiss remains pending before the Court, and the Company has no insight into when a decision will be issued. Further proceedings, such as discovery, have been stayed pending the Court’s decision on the motion to dismiss. The Company considers the counterclaim and the Apogee Litigation to be ordinary, routine litigation incidental to the business. The Company and Mukunda deny any and all liability and, in particular, deny many of the factual allegations contained in the Apogee Litigation. Both the Company and Mukunda intend to vigorously defend the litigation and are represented by counsel for that purpose.

As of December 31, 2021, the Company and two of its officers are parties to two shareholder lawsuits:

Tchatchou v. India Globalization Capital, Inc., et al., Civil Action No. 8:18-cv-03396 (U.S. District Court for the District of Maryland). On November 2, 2018, IGC shareholder Alde-Binet Tchatchou instituted a shareholder class action complaint on behalf of himself and all others similarly situated in the United States District Court for the District of Maryland. On May 13, 2019, the plaintiff filed an amended complaint against IGC, Ram Mukunda, and Claudia Grimaldi, (collectively, the “Class Action Defendants”). The plaintiff alleges that the Class Action Defendants violated Section 10(b) of the Exchange Act, SEC Rule 10b-5, and Section 20(a) of the Exchange Act and made false and misleading statements to the public by issuing a September 25, 2018, press release entitled “IGC to Enter the Hemp/CBD-Infused Energy Drink Space” and related disclosures, in which IGC announced it had “executed a distribution and partnership agreement” for the sugar-free energy drink named Nitro G, as well as through related public statements. On February 28, 2019, all pending shareholder class actions were consolidated, and the Tchatchou litigation was designated as the lead case. Throughout the Tchatchou litigation, the Class Action Defendants have denied any and all liability and denied any violation of the law.

Harris-Carr v. India Globalization Capital, Inc., et al., Civil Action No. 8:18-cv-03408 (U.S. District Court for the District of Maryland). On November 2, 2018, IGC shareholder Gabe Harris-Carr instituted a shareholder class action complaint on behalf of himself and all others similarly situated in the United States District Court for the District of Maryland. IGC, Ram Mukunda, and Claudia Grimaldi were named as defendants. On February 28, 2019, all pending shareholder class actions, including the Harris-Carr litigation, were consolidated, and the Tchatchou litigation, described above, was designated as the lead case. On May 13, 2019, the plaintiff in the Tchatchou litigation filed an amended complaint, which becomes the operative complaint for the consolidated matter and supersedes the Harris-Carr complaint. Throughout the Harris-Carr litigation, the Class Action Defendants have denied any and all liability and denied any violation of the law.

On October 20, 2021, the plaintiffs and the Class Action Defendants executed a Stipulation and Agreement of Settlement to settle all pending shareholder litigation, including the Tchatchou and Harris-Carr matters described above, for a total payment of $1,000,000.00. The settlement is subject to final approval by the United States District Court for the District of Maryland (“Court”). A final settlement approval hearing has been scheduled for April 13, 2022 before the Court. Of the total settlement amount, $847,245.00 is to be paid by the Company’s insurer; the Company has created a provision for the remaining $152,755.00. On January 11, 2022, all settlement proceeds were transmitted to a third-party for administration of the settlement. The Company and the Class Action Defendants are represented by counsel in the litigation.

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q

Item 1A. Risk Factors

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.


There have not been any material changes with regard to the risk factors previously disclosed in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2017.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

None.  

Item 3.    3. Defaults Upon Senior Securities

None.

None.

Item 4. Mine Safety Disclosures


Not applicable.

Item 5. Other Information

None.

None.

Item 6.    6. Exhibits

3.1

Exhibit

Number

Exhibit Description

3.1

Amended and Restated Articles of Incorporation of the Registrant, as amended on August 1, 2012 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed on August 6, 2012).

3.2

3.3

Amendment to the Amended and Restated Articles of Incorporation of the Registrant as amended on August 2, 2014 (incorporated by reference to Exhibit 3.3 to the Company’s Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).

4.1

Description of Common Stock (incorporated by reference to prospectus supplement filed on Oct 2, 2018 to Prospectus effective May 11, 2018).

10.01

Employment Agreement, effective as of November 18, 2021, by and between India Globalization Capital Inc. and Mr. Ram Mukunda (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 19, 2021). 

10.02

Restricted Stock Unit Agreement with CEO Mr. Ram Mukunda (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1, as amended andS-8 filed on February 14, 2006 (Reg. No. 333-124942))December 23, 2021).

31.1

31.1*

31.2*

Rule 13a-14(a) / 15d-14(a) Certification of Principal Executive OfficerFinancial Officer.

32.1**

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002. *§1350.

31.2

101.INS*

Inline XBRL Instance Document.

32.1

101.SCH*

32.2
101.INSXBRL Instance Document*
101.SCH

Inline XBRL Taxonomy Extension Schema Document*Document.

101.CAL

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document*Document.

101.LAB

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document*Document.

101.PRE

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document*Document.

101.DEF

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document*Document.

104*

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.

** Furnished herewith.



indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INDIA GLOBALIZATION CAPITAL, INC.

Date: February 20, 201810, 2022

By:

/s/ Ram Mukunda

Ram Mukunda

President and Chief Executive Officer and President

(Principal Executive Officer)

Date: February 20, 201810, 2022

By:

/s/ Rohit Goel

Claudia Grimaldi

Rohit Goel
Co-Principal Accounting Officer

Claudia Grimaldi

Vice President

(Principal Financial Officer)

indiaglob20211231_10qimg002.jpg | December 31, 2021, Form 10-Q
36
19
iso4217:USD xbrli:shares